UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant [ X ]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ X ] Preliminary Proxy Statement
[ ] Confidential, For Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material pursuant to Rule 14a-11(c) or Rule 14a-12
ENZON PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its Charter)
N/A
(Name of Person(s) filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X ] No fee required.
[ ] $500 per each party to the controversy pursuant to Exchange
Act Rule 14a-6(I)(3).
[ ] Fee computed on table below per Exchange Act
Rules 14a-6(I)(4) and 0-11.
(1) Title of each class of securities to which transaction
applies:
.................................................................................
(2) Aggregate number of securities to which transaction applies:
.................................................................................
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11: Set forth the
amount on which the filing fee is calculated and state how
it was determined.
.................................................................................
(4) Proposed maximum aggregate value of transaction:
.................................................................................
(5) Total fee paid.
.................................................................................
[ ] Check box if any part of the fee is offset as provided by Exchange Act
rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
.................................................................................
2) Form, Schedule or Registration Statement No.:
.................................................................................
3) Filing Party:
.................................................................................
4) Date Filed:
.................................................................................
ENZON PHARMACEUTICALS, INC.
[GRAPHIC OMITTED]
685 Route 202/206
Bridgewater, New Jersey 08807
(908) 541-8600
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 18, 2006
To our Stockholders:
The annual meeting of stockholders (the "Annual Meeting") of Enzon
Pharmaceuticals, Inc., a Delaware corporation ("Enzon" or the "Company") will be
held at the Sheraton Indianapolis Hotel and Suites, 8787 Keystone Crossing,
Indianapolis, Indiana 46240 on Thursday, May 18, 2006 at 9:00 a.m. local time,
for the following purposes:
1. To elect one Class I director, to serve for a term of three years until the
2009 Annual Meeting and until his successor is elected and qualified, in
accordance with the Company's Restated Certificate of Incorporation and
By-Laws (Proposal No. 1);
2. To approve the amendment of the 2001 Incentive Stock Plan to increase the
number of shares of common stock issuable thereunder by an additional
4,000,000 shares (Proposal No. 2);
3. To approve the amendment and restatement of our Restated Certificate of
Incorporation to increase the number of authorized shares of common stock
from 90,000,000 shares to 170,000,000 shares (Proposal No. 3);
4. To ratify the selection of KPMG LLP, independent registered public
accountants, to audit the consolidated financial statements of the Company
for the year ending December 31, 2006 (Proposal No. 4); and
5. To transact such other matters as may properly come before the Annual
Meeting or any adjournment thereof.
Only holders of record of the Company's common stock at the close of
business on April 6, 2006 are entitled to vote at the Annual Meeting.
We hope that as many stockholders as possible will personally attend the
Annual Meeting. Whether or not you plan to attend the Annual Meeting, your proxy
vote is important. To assure your representation at the meeting, please
complete, sign and date the enclosed proxy card and return it promptly in the
enclosed envelope. Sending in your proxy will not prevent you from voting in
person at the Annual Meeting.
By Order of the Board of Directors,
/s/ Paul S. Davit
Paul S. Davit
Corporate Secretary
Bridgewater, New Jersey
April __, 2006
The Company's Annual Report to Shareholders, including its Transition
Report for the six-month period ended December 31, 2005, accompanies this notice
but is not incorporated as part of the proxy statement and is not to be regarded
as part of the proxy solicitation materials.
ENZON PHARMACEUTICALS, INC.
[GRAPHIC OMITTED]
685 Route 202/206
Bridgewater, NJ 08807
(908) 541-8600
_______
PROXY STATEMENT
_______
This Proxy Statement and the enclosed proxy card and voting instructions
are being furnished to stockholders of record of Enzon Pharmaceuticals, Inc.
("Enzon" or the "Company") as of April 6, 2006, in connection with the
solicitation of proxies for use at the annual meeting of stockholders (the
"Annual Meeting") to be held on Thursday, May 18, 2006 at the Sheraton
Indianapolis Hotel and Suites, 8787 Keystone Crossing, Indianapolis, Indiana
46240 at 9:00 a.m. local time and at any postponement or adjournment thereof.
The accompanying proxy is solicited by the Board of Directors of Enzon and is
revocable by the stockholder any time before it is voted. For more information
concerning the procedure for revoking the proxy, see "General." This Proxy
Statement is being mailed to stockholders of the Company on or about April 18,
2006, accompanied by the Company's Annual Report to Stockholders, including its
Transition Report on Form 10-K for the six-month transition period ended
December 31, 2005. Enzon's principal executive offices are located at 685 Route
202/206 Bridgewater, New Jersey 08807, telephone (908) 541-8600.
Only holders of the Company's common stock, par value $.01 per share (the
"Common Stock" or "Common Shares") outstanding at the close of business on April
6, 2006 (the "Record Date") are entitled to receive notice of, and to vote at,
the Annual Meeting. As of the Record Date, there were _________ Common Shares
outstanding and entitled to vote at the meeting. Each Common Share is entitled
to one vote on all matters. No other class of securities will be entitled to
vote at the Annual Meeting. There are no cumulative voting rights.
To be elected, a director must receive a plurality of the votes of the
Common Shares present in person or represented by proxy at the Annual Meeting
and entitled to vote on the election of directors. The affirmative vote of at
least a majority of the Common Shares present in person or represented by proxy
at the Annual Meeting and entitled to vote thereon is necessary for approval of
Proposals No. 2 and No. 4. Approval of Proposal No. 3 requires the affirmative
vote of at least a majority of the Common Shares outstanding as of the Record
Date and entitled to vote thereon. A quorum is representation in person or by
proxy at the Annual Meeting of at least one-third of the Common Shares
outstanding as of the Record Date.
Pursuant to the Delaware General Corporation Law, only votes cast "For" a
matter constitute affirmative votes. Proxy cards that are voted by marking
"Withheld" or "Abstain" on a particular matter are counted as present for quorum
purposes and for purposes of determining the outcome of such matter, but because
they are not cast "For" a particular matter, they will have the same effect as
negative votes or votes cast "Against" a particular matter. If a validly
executed proxy card is not marked to indicate a vote on a particular matter and
the proxy granted thereby is not revoked before it is voted, it will be voted
"For" such matter. Where brokers are prohibited from exercising discretionary
authority for beneficial owners who have not provided voting instructions
(commonly referred to as "broker non-votes"), such broker non-votes will be
treated as shares that are present for purposes of determining the presence of a
quorum; however, with respect to proposals which require the affirmative vote of
a percentage of shares present at the Annual Meeting for approval, such broker
non-votes will be treated as not present for purposes of determining the outcome
of any such matter. With respect to proposals that require the affirmative vote
of a percentage of the outstanding shares for approval, because such broker
non-votes are not cast "For" a particular matter, they will have the same effect
as negative votes or votes cast "Against" such proposals.
The cost of proxy solicitation, including the cost of reimbursing banks and
brokers for forwarding proxies and proxy statements to beneficial owners of the
Common Stock, will be paid by the Company. Proxies may be solicited without
extra compensation by some of the officers and other employees of the Company by
telephone or personal interviews. The Company has also retained D.F. King & Co.,
Inc. to assist in the solicitation of proxies at an anticipated fee of $______
plus out-of-pocket expenses.
PROPOSAL NO. 1 - ELECTION OF DIRECTORS
Pursuant to the provisions of the Company's Restated Certificate of
Incorporation and By-laws, the Board of Directors is comprised of three classes
of directors, designated Class I, Class II and Class III. One class of directors
is elected each year to hold office until the third annual meeting of
stockholders after such election and until successors of such directors are duly
elected and qualified. The Governance and Nominating Committee has recommended
to the Board, and the Board also recommends that the stockholders elect the
Class I director nominee at this year's Annual Meeting to serve until the 2009
Annual Meeting and until his successor is elected and qualified. Currently, the
Board has set the number of directors at eight. One of our current Class I
directors, Dr. Rosina B. Dixon, is retiring as of April 30, 2006. The Governance
and Nominating Committee is currently evaluating candidates to fill the vacancy
that will be created by Dr. Dixon's retirement, but has not yet chosen a
nominee. The proxies solicited by this Proxy Statement cannot be voted for more
than one nominee at the Annual Meeting. The nominee for election to the office
of director, and certain information with respect to his background and the
backgrounds of non-nominee directors, are set forth below. It is the intention
of the persons named in the accompanying proxy card, unless otherwise
instructed, to vote to elect the nominee named herein as Class I director. In
the event the nominee named herein is unable to serve as a director,
discretionary authority is reserved to the Board of Directors to vote for a
substitute. The Board of Directors has no reason to believe that the nominee
named herein will be unable to serve if elected.
The name, age and year in which the term expires of each member of or
nominee for election to the Board of Directors of the Company is set forth below
Term Expires on the
Director Position with Annual Meeting Held
Nominee Age Since the Company In The Year
- --------------------------- ---- --------- -------------------------- ---------------
Jeffrey H. Buchalter 48 2004 Chief Executive Officer and 2007
Chairman of the Board
Goran A. Ando, M.D. 57 2004 Director 2007
Victor P. Micati 66 2004 Director 2007
Rolf A. Classon 60 1997 Director 2008
Robert LeBuhn 73 1994 Director 2008
Robert C. Salisbury 62 2005 Director 2008
Phillip M. Renfro 60 2005 Director 2006
Rosina B. Dixon, M.D. 63 1994 Director *
- -----------------------------------------------------------------------------------------------------------------------------------
* Dr. Dixon is retiring from the Company's Board of Directors effective April 30, 2006.
2
BUSINESS EXPERIENCE OF DIRECTORS
Class I Director Nominee for Election at the 2006 Annual Meeting
Phillip M. Renfro, age 60, has served as a director of the Company since
January 2005. Mr. Renfro has been a partner at the law firm of Fulbright &
Jaworski, L.L.P. since 1984. Prior to joining Fulbright & Jaworski, Mr. Renfro
was Chief Executive Officer of Resco International, an international oilfield
service company and Vice President and General Counsel of Weatherford
International, one of the largest international oilfield service companies in
the United States from 1977 to 1983.
The Board of Directors recommends a vote FOR Mr. Renfro as Class I Director
(Proposal No. 1 on the Proxy Card).
Non-Nominee Class II Directors Serving Until the 2007 Annual Meeting
Jeffrey H. Buchalter, age 48, has served as a director of the Company and
as Chairman of the Board of Directors since September 2004 and as President,
Chief Executive Officer since December 2004. Mr. Buchalter previously served as
the President and Chief Executive Officer of Ilex Oncology, Inc. from January
2002 until December 2004, serving as President of Ilex from September 2001 until
December 2002. Mr. Buchalter was also a director of Ilex from February 2001
until December 2004. From 1997 to 2001, Mr. Buchalter was Group Vice President
for the Worldwide Oncology Franchise at Pharmacia Corporation. From 1993 to
1997, Mr. Buchalter was a Group Director with American Home Products, Wyeth
Ayerst Laboratories. Mr. Buchalter was presented the Joseph F. Buckley Memorial
Award from the American Cancer Society for commitment to cancer control and
involvement in the pharmaceutical oncology field. Additionally, Mr. Buchalter
was invited by former President George Bush to serve as a collaborating partner
in the National Dialogue on Cancer.
Goran A. Ando, M.D., age 57, has served as a director of the Company since
November 2004. From April 2003 through July 2004, he served as Chief Executive
Officer of Celltech Group plc. Prior to joining Celltech in April 2003, Dr. Ando
served in various senior posts at Pharmacia Corporation. In his most recent role
at Pharmacia, Dr. Ando was Executive Vice President and President of R&D and
also had executive responsibilities for IT, manufacturing and business
development. Prior to his most recent role with Pharmacia, Dr. Ando held various
executive positions, including Executive Vice President & Deputy Chief Executive
Officer, Pharmacia AB, Sweden; Executive Vice President, Worldwide Science &
Technology, Pharmacia & Upjohn, UK; and Chairman, Pharmacia & Upjohn AB, Sweden.
Prior to joining Pharmacia, Dr. Ando held various senior positions with Glaxo
Ltd., Bristol Myers International Group, and Pfizer International.
Victor P. Micati, age 66, has served as a director of the Company since
November 2004. Mr. Micati is a retired senior executive of Pfizer Inc. In 1999,
Mr. Micati retired from Pfizer where he most recently served as Executive Vice
President of the Pharmaceutical Group of Pfizer and Vice President of Pfizer
Inc. Mr. Micati first joined Pfizer in 1965 and over a 34-year career served in
numerous capacities, including: President of European Operations; Executive Vice
President of Pfizer Europe; Senior Vice President, Pharmaceuticals; Vice
President of Pharmaceutical Development, Pfizer International; and Vice
President of Marketing, Pfizer Laboratories. Mr. Micati also served as a member
of the Pfizer International Board of Directors. Mr. Micati is currently a
consultant to the pharmaceutical industry and is a member of the Board of
Trustees of the Monterey Institute.
Non-Nominee Class III Directors Serving Until the 2008 Annual Meeting
Rolf A. Classon, age 60, has served as a director of the Company since
January 1997. Since May 2005, Mr. Classon has served as interim CEO for
Hillenbrand Industries. From 2002 to 2004, Mr. Classon served as Chairman of the
Executive Committee of Bayer Healthcare AG and, from 1995 to 2002, Mr. Classon
served as an Executive Vice President of Bayer Corporation and President of
Bayer Diagnostics. From 1991 to 1995, Mr. Classon was an Executive Vice
President in charge of Bayer Diagnostics' Worldwide Marketing, Sales and Service
operations. From 1990 to 1991, Mr. Classon was President and Chief Operating
Officer of Pharmacia Biosystems A.B. Prior to 1991, Mr. Classon served as
President of Pharmacia Development Company Inc. and Pharmacia A.B.'s Hospital
Products Division. Mr. Classon currently serves as a director of ISTA
Pharmaceuticals, Auxilium Pharmaceuticals, Millipore Corporation and Hillenbrand
Industries.
3
Robert LeBuhn, age 73, has served as a director of the Company since August
1994. Mr. LeBuhn is a private investor. He is a Trustee and Chairman of the
Geraldine R. Dodge Foundation, a Trustee and Treasurer of All Kinds of Minds, a
Trustee of Executive Service Corp., and a Trustee of the Aspen Music Festival
and School and President of its National Council.
Robert C. Salisbury, age 62, has served as a director of the Company since
May 2005. In 1998, Mr. Salisbury retired from Pharmacia & Upjohn, Inc. where he
most recently served as Executive Vice President and Chief Financial Officer.
Previously, Mr. Salisbury served as Executive Vice President, Finance and Chief
Financial Officer at The Upjohn Company. Mr. Salisbury first joined The Upjohn
Company in 1974 and over a career of more than 20 years, he served in various
management posts in finance and strategic planning. Mr. Salisbury currently
serves as a director of Viragen, Inc.
There are no family relationships among any of the Company's directors or
executive officers.
DIRECTORS' NOMINATION
Process for Identifying and Evaluating Nominees. The Charter of the
Governance and Nominating Committee specifies the process for nominating persons
for election to the Board. The committee will solicit nominations for new
directors and screen the list of potential new directors submitted to it by
other directors or any other sources and decide whether the assistance of a
search firm is needed, and if so, choose the firm. After a review of board
candidates and after considering the advice of the Chairman of the Board and the
Chief Executive Officer, the committee will designate which candidates are to be
interviewed. Candidates will be interviewed by the chairman of the Governance
and Nominating Committee, the Chairman of the Board and the Chief Executive
Officer and may be interviewed by other directors of the Company. After the
interviews are completed, the committee will recommend to the Board which
individuals it approves as nominees for membership on the Board. Current
directors standing for reelection are not required to participate in an
interview process.
Criteria for Board Membership. The Charter of the Governance and Nominating
Committee does not set forth the specific criteria for identifying and
recommending new candidates to serve as directors, however, candidates will be
interviewed by the Governance and Nominating Committee to evaluate the
following, among other qualifications it may deem appropriate:
o experience as a director of another publicly-traded corporation,
experience in industries or with technologies relevant to the Company,
accounting or financial reporting experience, or such other professional
experience that the Governance and Nominating Committee determines qualifies an
individual for Board service;
o candidates' business judgment and temperament, ethical standards, view of
the relative responsibilities of a director and management, independent
thinking, articulate communication and intelligence; and
o any other factors as the Governance and Nominating Committee deems
appropriate, including judgment, skill, diversity, experience with businesses
and other organizations of comparable size, the interplay of the candidate's
experience with the experience of other Board members, and the extent to which
the candidate would be a desirable addition to the Board and any committees of
the Board.
Stockholder Nominees. The Governance and Nominating Committee will consider
written proposals from stockholders for nominees for director. Any such
nominations should be submitted to the Governance and Nominating Committee c/o
the Secretary of the Company and should include the following information: (a)
all information relating to such nominee that is required to be disclosed
pursuant to Regulation 14A under the Securities Exchange Act of 1934 (including
such person's written consent to being named in the proxy statement as a nominee
and to serving as a director if elected); (b) the names and addresses of the
stockholders making the nomination and the number of shares of Common Stock that
are owned beneficially and of record by such stockholders; and (c) appropriate
biographical information and a statement as to the qualification of the nominee.
4
This information should be submitted in the time frame described in the Bylaws
of the Company and under the caption, "Stockholder Proposals for 2007 Annual
Meeting" below. The manner in which the committee evaluates potential directors
will be the same for candidates recommended by the stockholders as for
candidates recommended by others.
Board Nominees for the 2006 Annual Meeting. The Governance and Nominating
Committee recommended that Mr. Renfro, one of our current Class I directors, be
nominated for re-election, Mr. Renfro was elected by the Board in January 2005
to fill a vacancy on the Board. Mr. Renfro was initially identified as a
director candidate by Mr. Buchalter. Mr. Buchalter and Mr. Micati each knew Mr.
Renfro in connection with Mr. Renfro's role as outside legal counsel to the
board of directors of Ilex Oncology, Inc., where he advised the Ilex board on
corporate governance matters. Prior to his election as a director by the Board,
Mr. Renfro was interviewed by each of the members of the Board at that time,
including Messrs. Buchalter, Classon and LeBuhn, and Drs. Ando and Dixon, other
than Mr. Micati. The Governance and Nominating Committee determined that Mr.
Renfro's experience and expertise, including his extensive knowledge of
corporate governance matters, would be valuable to the Board and would
strengthen the Board's overall expertise and capabilities. Upon the
recommendation of the Governance and Nominating Committee, the Board elected Mr.
Renfro to serve as an independent director of the Company. Our other current
Class I director, Dr. Dixon, is retiring from the Board as of April 30, 2006 and
therefore is not standing for re-election. The Governance and Nominating
Committee is currently evaluating potential candidates to fill the vacancy that
will be created by Dr. Dixon's retirement. The proxies solicited by this Proxy
Statement cannot be voted for more than one nominee at the Annual Meeting.
DIRECTORS' COMPENSATION
In September 2004, the Board of Directors adopted a new compensation plan
for non-employee directors, which was amended in May 2005 (the "2004 Outside
Director Compensation Plan"). Under the 2004 Outside Director Compensation Plan,
each non-employee director will receive an option to purchase 15,000 shares of
Common Stock annually on the first trading day of the calendar year (the "Annual
Option Grant") and a grant of restricted stock units for shares of Common Stock
with a value of $25,000 on the first trading day after June 30 (the "Annual
Restricted Stock Grant"). These grants are made under the 2001 Incentive Stock
Plan. The exercise price of the Annual Option Grant will be equal to the closing
price of the Common Stock on the date of grant and the number of shares issued
pursuant to the Annual Restricted Stock Grant will be equal to $25,000 divided
by the closing price of the Common Stock on the date of grant. The Annual Option
Grant vests in one tranche on the first anniversary of the date of grant if the
recipient director remains on the Board on that date. Once vested, options
granted pursuant to the Annual Option Grant expire on the 10th anniversary of
the date of grant. The shares covered by the Annual Restricted Stock Grant vest
in three equal tranches on each of the first three anniversaries of the date of
grant if the recipient director remains on the Board on each such date. Upon the
election of a new non-employee director to the Board, such newly elected
director will receive a grant of options to purchase 20,000 shares of Common
Stock (the exercise price of which will be equal to the closing price of the
Common Stock on the date of grant) and a grant of restricted stock units for
shares of Common Stock with a value of $25,000 (the number of shares covered by
such grant being equal to $25,000 divided by the closing price of the Common
Stock on the date of grant) (the "Welcome Grant"). The options and restricted
stock units included in the Welcome Grant vest in three equal tranches on each
of the first three anniversaries of the date of grant, if the recipient director
remains on the Board on each such date. Furthermore, for the Chairperson of the
Board, if not an employee of the Company, the number of option shares and
restricted stock units covered by the Annual Option Grant, Annual Restricted
Stock Grant and Welcome Grant are twice the numbers mentioned above.
In addition, under the 2004 Outside Director Compensation Plan, each
non-employee director receives an annual cash retainer of $20,000. Non-employee
directors also receive an additional annual cash retainer of $7,000 for service
as chair of the Finance and Audit Committee and $3,500 for service as chair of
any other committee. Further, each non-employee director is entitled to a cash
meeting fee of $1,500 for each meeting of the Board attended and each committee
meeting attended (whether in person or by teleconference).
Directors who are employees of the Company do not receive compensation for
their service on our Board of Directors.
5
During the fiscal year ended June 30, 2005, the Company recorded the
following fees earned:
Value # Shares
Total Cash of Stock Underlying Restricted
Board Member Compensation Compensation Compensation Stock Units
- ----------------------- ------------------ --------------------- ---------------- ------------------------
Goran Ando(1) $48,467 $23,467 $25,000 1,566
Jeffrey Buchalter(2) 59,845 9,845 50,000 3,234
Rolf Classon 77,000 52,000 25,000 1,989
Rosina Dixon 79,443 54,443 25,000 1,989
David Golde(3) 28,481 3,481 25,000 1,989
Arthur Higgins(4) 43,154 18,154 25,000 1,989
Robert LeBuhn 85,000 60,000 25,000 1,989
Victor Micati(5) 49,717 24,717 25,000 1,566
Phillip Renfro(6) 46,140 21,140 25,000 1,896
Robert Salisbury(7) 30,722 5,722 25,000 3,597
------------------ --------------------- ---------------- ------------------------
Totals $547,969 $272,969 $275,000 21,804
================== ===================== ================ ========================
(1) Dr. Ando joined the Board of Directors in November 2004
(2) Mr. Buchalter joined the Board of Directors as non-executive Chairman in
September 2004 and became President and Chief Executive Officer in December
2004
(3) Dr. Golde passed away in August 2004
(4) Mr. Higgins resigned from the Board of Directors in December 2004
(5) Mr. Micati joined the Board of Directors in November 2004
(6) Mr. Renfro joined the Board of Directors in January 2005
(7) Mr. Salisbury joined the Board of Directors in May 2005
During the six-month transition period ended December 31, 2005, the Company
recorded the following fees earned:
# Shares
Value Underlying
Total Cash of Stock Restricted Stock
Board Member Compensation Compensation Compensation Units
- ------------------------ ----------------- ------------------- ------------------- --------------------
Goran Ando $45,750 $20,750 $25,000 3,765
Rolf Classon 56,250 31,250 25,000 3,765
Rosina Dixon 39,500 14,500 25,000 3,765
Robert LeBuhn 59,500 34,500 25,000 3,765
Victor Micati 45,500 20,500 25,000 3,765
Phillip Renfro 51,750 26,750 25,000 3,765
Robert Salisbury 50,000 25,000 25,000 3,765
----------------- ------------------- ------------------- --------------------
Totals $348,250 $173,250 $175,000 26,355
================= =================== =================== ====================
Directors' Stock Ownership Program
In October 2000, the Board of Directors implemented a directors' stock
ownership program that requires each of the directors to beneficially own Common
Stock with a market value of at least $100,000 within two years after the
director first joins the Board of Directors. The determination of whether the
shares beneficially owned by a director meet the $100,000 minimum market value
requirement will be based on the highest average trading price of the Common
Stock over any consecutive twenty trading days during the two year period after
the director first joins the Board of Directors or the price paid for the Common
Stock by the director. Shares of Common Stock underlying options held by the
directors will not be counted towards satisfaction of this requirement. The
Board of Directors may waive this requirement under certain circumstances. Each
of the Company's current directors that have served on the Board of Directors
for two years or more meet this requirement.
6
INFORMATION CONCERNING THE BOARD AND COMMITTEES OF THE BOARD
Independence of Directors
The Company's Board of Directors is composed entirely of independent
outside directors, with the exception of the Chief Executive Officer. The
committees of the Board are also composed entirely of independent outside
directors, with the exception of the Executive Committee, of which the Chief
Executive Officer is a member.
The Board has determined that the following directors, comprising all of
the directors other than the Chief Executive Officer, are "independent" under
current NASDAQ rules: Messrs. Classon, LeBuhn, Micati, Renfro and Salisbury and
Drs. Ando and Dixon.
Meetings and Attendance
The Company's Board of Directors held ten meetings during the fiscal year
ended June 30, 2005 and held two meetings during the six-month transition period
ended December 31, 2005. Each director attended at least 75% of the total number
of meetings of the Board of Directors, and committees of the Board of Directors
of which such director was a member, held during each of those periods.
The independent directors of the Board hold at least two executive sessions
each year at which only the independent directors are present. In 2005, the
independent directors held two executive sessions. Mr. Micati is the Lead
Independent Director and presiding director at these executive sessions for
2006.
Enzon does not have a policy requiring the directors to attend the annual
stockholders' meeting. However, all of the Company's directors in office at the
time of our last annual stockholders' meeting attended that meeting. It is
expected that all of our directors then in office will attend the 2006 Annual
Meeting.
Communications with Directors
Stockholders may communicate directly with the directors. All
communications should be sent in care of the Secretary of Enzon at Enzon's
address and should prominently indicate on the outside of the envelope that it
is intended for the Board of Directors, for a specific non-employee director or
a particular committee of the Board. If no director is specified, the
communication will be forwarded to the entire Board.
Standing Committees of the Board of Directors
Enzon's Board of Directors currently has the following standing committees:
Finance and Audit Committee, Compensation Committee, Governance and Nominating
Committee, Executive Committee and Scientific and Technology Committee.
Finance and Audit Committee. The Finance and Audit Committee currently
consists of Messrs. Salisbury (Chairman), Classon, LeBuhn and Renfro. In
compliance with audit committee requirements for Nasdaq companies, the Board has
determined that all members of the Finance and Audit Committee are independent,
as independence is defined in Rule 4200(a)(15) of the National Association
Securities Dealers ("NASD") listing standards and Section 10A(m)(3) of the
Securities Exchange Act of 1934. Each of the members is able to read and
understand financial statements. The Board has determined that the Chairman of
7
the committee, Mr. Salisbury, and two other members of the committee each
qualifies as an "audit committee financial expert" as defined in Item 401(h) of
Regulation S-K under the Securities Exchange Act of 1934. The primary purpose of
the Finance and Audit Committee is to assist the Board of Directors in its
oversight responsibilities by monitoring the integrity of the Company's
financial reporting process and financial statements, the systems of internal
controls and controls over financial reporting, the compliance by the Company
with legal and regulatory requirements, and the performance and independence of
the Company's independent auditors. The committee meets periodically with
management to consider the adequacy of our internal control and the financial
reporting process. It also discusses these matters with our independent
auditors. The committee reviews our financial statements and discusses them with
management and the independent auditors before those financial statements are
filed with the Securities and Exchange Commission. The Finance and Audit
Committee adopted a written charter during fiscal 2000 and amended its charter
in September 2002 and March 2006. A copy of the charter of the Finance and Audit
Committee as amended is attached to this Proxy Statement as Appendix A. The
Charter may also be found on our website at www.enzon.com. The Finance and Audit
Committee held ten meetings during the fiscal year ended June 30, 2005 and eight
meetings during the six-month transition period ended December 31, 2005.
Compensation Committee. The Compensation Committee currently consists of
Dr. Ando (Chairman) and Messrs. Classon and Micati. The Board has determined
that all members of the Compensation Committee are independent, as independence
is defined in Rule 4200(a)(15) of the NASD listing standards. The primary
functions of the Compensation Committee are to administer the Company's 1987
Non-Qualified Stock Option Plan and 2001 Incentive Stock Plan, determine the
compensation of the Company's officers and senior management, and review
compensation policy. The Charter of the Compensation Committee may be found on
our website at www.enzon.com. There were five meetings of the Compensation
Committee during the fiscal year ended June 30, 2005 and three meetings during
the six-month transition period ended December 31, 2005.
Governance and Nominating Committee. The Governance and Nominating
Committee currently consists of Messrs. Renfro (Chairman), Micati and Salisbury.
The Board has determined that all of the members of the Governance and
Nominating Committee are independent as defined in Rule 4200(a)(15) of the NASD
listing standards. This committee reviews and sets corporate governance policy
and is responsible for making recommendations to the Board on Board organization
and procedures, performance evaluation of the Board and individual directors,
and nomination of directors. The Governance and Nominating Committee's Charter
may be found on our website at www.enzon.com. There were five meetings of the
Governance and Nominating Committee during the fiscal year ended June 30, 2005
and one meeting during the six-month transition period ended December 31, 2005.
Executive Committee. The Executive Committee currently consists of Mr.
Buchalter (Chairman), Dr. Ando, and Messrs. Classon and Micati. In between
meetings of the Board of Directors, the Executive Committee exercises the
authority and power of the Board to the full extent permitted under Delaware
Law.
Scientific and Technology Committee. The Scientific and Technology
Committee currently consists of Dr. Ando (Chairman), and Messrs. Micati and
Renfro. This committee provides scientific input to the Board of Directors and
serves as the liaison between the Company's senior research and development
management and the Board of Directors.
CODE OF CONDUCT
The Board of Directors has adopted a Code of Conduct that is applicable to
all of our directors, officers and employees. Any material changes made to the
Code of Conduct or any waivers granted to any of our directors and executive
officers will be publicly disclosed by the filing of a Current Report on Form
8-K within four business days of such material change or waiver. A copy of our
Code of Conduct is available on the Corporate Governance page of our website at
www.enzon.com or upon request, without charge, by contacting our Investor
Relations Department by calling 908-541-8777 or through an e-mail request to
investor@enzon.com.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The current members of our Compensation Committee are Dr. Ando (Chairman)
and Messrs. Classon and Micati. There are no interlocks among any of the members
of our Compensation Committee and any of our executive officers.
8
BUSINESS EXPERIENCE OF EXECUTIVE OFFICERS
Set forth below is certain information regarding the executive officers of
the Company who do not serve on the Board of Directors.
Paul S. Davit, age 51, has served as the Company's Executive Vice
President, Human Resources since April 2005. Mr. Davit previously served as
Enzon's Senior Vice President, Human Resources from January 2004 to April 2005,
and Vice President, Human Resources from March 2002 to January 2004. Prior to
joining Enzon, Mr. Davit ran a human resources consulting practice from
September 2001 to March 2002. From July 1998 to September 2001, Mr. Davit
worked at Caliber Associates and he spent over 11 years with Rhone-Poulenc Rorer
from October 1986 to May 1998, where he served as Vice President of Human
Resources for RPR Gencell, Rhone-Poulenc Rorer's start-up biotechnology division
and as Vice President of Human Resources for the North American Pharmaceuticals
division. Mr. Davit began his career as a compensation consultant with the Hay
Group.
Ralph del Campo, age 54, has served as the Company's Executive Vice
President, Technical Operations since April 2005. Mr. del Campo has over 30
years of diverse industry experience, including serving as Enzon's Senior Vice
President, Technical Operations from October 2002 to April 2005. Prior to
joining Enzon, Mr. del Campo was the head of the North American operations of
Elan Corporation, plc from May 2000 to September 2002. Mr. del Campo also spent
over 17 years in various senior operations management positions at Bristol-Myers
Squibb.
Dr. Ivan D. Horak, age 55, has served as the Company's Executive Vice
President of Research and Development and Chief Scientific Officer since
September 2005. Prior to joining Enzon, Dr. Horak was employed by Immunomedics,
Inc. as Executive Vice President of Research and Development from May 2002 until
July 2003, and as Chief Scientific Officer from July 2003 to August 2005. Before
joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President
for Clinical Oncology from November 1999 to May 2002, where he helped direct the
global development of oncology compounds, including Camptosar(R) for metastatic
colorectal cancer. From 1996 to 1999, Dr. Horak held a variety of clinical
research positions at Janssen Research Foundation, a subsidiary of the Johnson &
Johnson Company, including International Director for Clinical Research and
Development, Oncology. Prior to joining Janssen, Dr. Horak spent nine years at
the National Cancer Institute where he most recently served as a cancer expert
for the Metabolism Branch. In addition to authoring over 60 scientific
publications, Dr. Horak is a member of several prominent medical societies and
has served on various committees for the American Association for Cancer
Research and the International Union Against Cancer. He also serves on the
editorial board of the prestigious journal, Cancer Research. He is a fellow of
the American College of Physicians. Dr. Horak received his M.D. degree from the
University of Komenius, Bratislava, Czechoslovakia.
Craig A. Tooman, age 40, has served as the Company's Executive Vice
President, Finance and Chief Financial Officer since June 2005. Mr. Tooman
served as the Company's Executive Vice President, Strategic Planning and
Corporate Communications from January 2005 to June 2005, and he retained the
duties of that position when he was appointed to the position of Executive Vice
President, Finance and Chief Financial Officer. Prior to joining Enzon, from
2002 to 2005, Mr. Tooman served as Senior Vice President of Strategic Planning
and Corporate Communications for Ilex Oncology, Inc. Before joining Ilex, Mr.
Tooman worked at Pharmacia Corporation where he most recently served as Vice
President of Investor Relations from 2000 to 2001. Previously, Mr. Tooman served
in various management posts at Pharmacia & Upjohn, including Assistant Vice
President of Investor Relations from 1999 to 2000 and Worldwide Director of
Investor Relations from 1998 to 1999. Prior to the merger of Pharmacia and
Upjohn, Mr. Tooman held various management positions for the Upjohn Company,
including assignments in Europe and Japan.
9
SUMMARY COMPENSATION TABLE
The following table provides a summary of cash and non-cash compensation
for each of the last three fiscal years ended June 30, 2005, 2004 and 2003 and
the six-month transition period ended December 31, 2005 with respect to the
Company's Chief Executive Officer and the Company's next four most highly
compensated executive officers for the fiscal year ended June 30, 2005 and the
six-month transition period ended December 31, 2005, and two individuals for
whom disclosure would have been provided as one of the next four most highly
compensated executive officers but for the fact that they were not serving as
executive officers of the Company at the end of the last completed fiscal year
(the "Named Executive Officers"):
Long-Term
----------------------------
Compensation
Annual Compensation Awards
--------------------------------------------- ----------------------------
Restricted
Other Annual Stock Securities
Name and Compensation Awards Underlying
Principal Position Year Salary($) Bonus(S) ($)(1)(3) ($)(2) Options(#)
- -------------------------------------- -------- ---------- ------------ ---------------- ------------- ---------------
- -------------------------------------- -------- ---------- ------------ ---------------- ------------- ---------------
Jeffrey H. Buchalter 2005* $296,154 $412,500(4) $229,966(5) $836,400(8) 300,000
Chairman of the Board 2005 260,192 550,000(4) 229,789(5) 1,065,498(8) 1,515,000
President, Chief Executive Officer
Craig A. Tooman 2005* 197,308 150,000(4) 201,704(6) 69,700(9) 50,000
Executive Vice President, Finance 2005 136,904 300,000(4) 101,631(6) 431,250(9) 225,000
Chief Financial Officer
Ralph del Campo(15) 2005* 188,462 100,000(4) 7,890 69,700(10) 50,000
Executive Vice President 2005 331,327 200,000(4) 5,648 104,250(10) 50,000
Technical Operation
Paul S. Davit(15) 2005* 161,538 75,000(4) 3,596 69,700(11) 50,000
Executive Vice President 2005 283,017 175,000(4) 6,115 104,250(11) 50,000
Human Resources
Ivan D. Horak, M.D. 2005* 132,404 165,000(4) - 409,275(12) 235,000
Executive Vice President
Research and Development
and Chief Scientific Officer
Ulrich Grau Ph.D.(16) 2005* - - - - -
Chief Scientific Officer 2005 391,227 - 539,602(7) - -
2004 423,942 210,590 4,687 614,875(13) 100,000
2003 400,000 185,000 8,019 - 50,000
Kenneth J. Zuerblis(17) 2005* - - - - -
Executive Vice President, 2005 314,708 - 617,385(7) - -
Finance, Chief Financial 2004 319,327 258,560 7,000 514,300(14) 125,000
Officer and Corporate 2003 303,235 147,000 6,776 - 50,000
Secretary
___________________________
* For the six-month period ended December 31, 2005.
(1) Excludes perquisites and other personal benefits that in the aggregate do
not exceed the lesser of $50,000 or 10% of the Named Executive Officer's
total annual salary and bonus.
(2) Calculated by multiplying the amount of restricted stock by the closing
market price on the date of the restricted stock grant.
(3) Includes annual Company contributions to a 401(k) plan.
10
(4) The amounts represent performance bonuses for the fiscal year ended June
30, 2005 and the six months ended December 31, 2005. Mr. Buchalter's bonus
for the fiscal year ended June 30, 2005 includes a guaranteed minimum bonus
of $412,500 payable under his employment agreement. Mr. Tooman's bonus
includes a $125,000 sign-on bonus paid in January 2005. Dr. Horak's bonus
includes a $100,000 sign-on bonus paid in September 2005 and a performance
bonus for the six months ended December 31, 2005.
(5) The amounts include reimbursements related to Mr. Buchalter's temporary
living and relocation expenses of $215,539 for the fiscal year ended June
30, 2005 and $186,649 of temporary living and relocation expenses for the
six months ended December 31, 2005.
(6) The amounts include reimbursements related to Mr. Tooman's temporary living
and relocation expense of $87,381 for the fiscal year ended June 30, 2005
and $188,586 for the six months ended December 31, 2005.
(7) Amounts include payments made to Dr. Grau and Mr. Zuerblis in accordance
with their respective Separation Agreements and annual Company
contributions to a 401(K) plan. For additional information on the
Separation Agreements, see "Employment and Separation Agreements."
(8) Amount represents an award of 75,000 shares of restricted stock granted on
December 22, 2004, an award of 3,234 shares of restricted stock units
granted on September 28, 2004 and an award of 120,000 shares of restricted
stock units granted on November 23, 2005. Mr. Buchalter's 75,000 shares of
restricted stock and 120,000 shares of restricted stock units vest as to
30% of the shares on the third anniversary of the grant date, 30% on the
fourth anniversary of the grant date, and 40% on the fifth anniversary of
the grant date. Mr. Buchalter's 3,234 restricted stock units vest as to
one-third of the shares on the first anniversary of the grant date,
one-third of the shares on the second anniversary of the grant date, and
one-third of the shares on the third anniversary of the grant date. Mr.
Buchalter's shares of restricted stock and restricted stock units had an
aggregate value of $507,000 as of June 30, 2005 and an aggregate value of
$1,467,000 as of December 31, 2005.
(9) Amount represents awards of 25,000 shares of restricted stock granted on
January 5, 2005, 15,000 shares of restricted stock units granted on May 12,
2005 and 10,000 shares of restricted stock units granted on November 23,
2005. Mr. Tooman's restricted stock and restricted stock units vest as to
30% of the shares on the third anniversary of the grant date, 30% on the
fourth anniversary of the grant date, and 40% on the fifth anniversary of
the grant date. As of June 30, 2005, Mr. Tooman's restricted stock and
restricted stock units had an aggregate value of $259,000 and an aggregate
value of $370,000 as of December 31, 2005.
(10) Amount represents awards of 15,000 shares of restricted stock units granted
on May 12, 2005 and 10,000 shares of restricted stock units on November 23,
2005. Mr. del Campo's restricted stock units vest as to 30% of the shares
on the third anniversary of the grant date, 30% on the fourth anniversary
of the grant date, and 40% on the fifth anniversary of the grant date. As
of June 30, 2005, Mr. del Campo's restricted stock units had an aggregate
value of $97,000 and an aggregate value of $185,000 as of December 31,
2005.
(11) Amount represents awards of 15,000 restricted stock units granted on May
12, 2005 and 10,000 shares of restricted stock units on November 23, 2005.
Mr. Davit's restricted stock units vest as to 30% of the shares on the
third anniversary of the grant date, 30% on the fourth anniversary of the
grant date, and 40% on the fifth anniversary of the grant date. As of June
30, 2005, Mr. Davit's shares of restricted stock units had an aggregate
value of $97,000 and an aggregate value of $185,000 as of December 31,
2005.
(12) Amount represents awards of 50,000 shares of restricted stock units granted
on September 2, 2005, pursuant to his employment agreement and 7,500 shares
of restricted stock units granted on November 23, 2005. Dr. Horak's
restricted stock units vest as to 30% of the shares on the third
anniversary of the grant date, 30% on the fourth anniversary of the grant
date, and 40% on the fifth anniversary of the grant date. As of December
31, 2005, Dr. Horak's restricted stock units had an aggregate value of
$426,000.
(13) Amount represents awards of 40,000 shares of restricted stock granted on
December 5, 2003 and 12,500 restricted stock units granted on February 6,
2004. Dr. Grau's shares of restricted stock and restricted stock units were
cancelled in March 2005 in accordance with his Separation Agreement.
(14) Amount represents awards of 12,500 restricted stock units granted on
February 6, 2004 and 27,500 shares of restricted stock granted on June 14,
2004. Mr. Zuerblis' restricted stock vested as to 100% of the shares and
his restricted stock units were cancelled upon his resignation in April
2005 in accordance with his Separation Agreement. As of June 30, 2005, Mr.
Zuerblis' shares of restricted stock had an aggregate value of $178,000.
11
(15) In April 2005, Messrs. del Campo and Davit were named as executive officers
of the Company.
(16) In November 2004, the Company entered into a separation agreement with Dr.
Grau in connection with his decision to voluntarily resign as the Company's
Chief Scientific Officer.
(17) In April 2005, the Company entered into a separation agreement with Mr.
Zuerblis in connection with his decision to voluntarily resign from his
position as the Company's Executive Vice President, Finance and Chief
Financial Officer.
OPTION GRANTS DURING LAST FISCAL YEAR AND
SIX-MONTH PERIOD ENDED DECEMBER 31, 2005
The following table contains information concerning the grant of stock
options under the Company's stock option plans to the Named Executive Officers
during the fiscal year ended June 30, 2005:
Individual Grants
-------------------------------------------------------
% of Total Potential Realizable Value at
Number of Options Assumed Annual Rates of Stock
Securities Granted to Exercise Price Appreciation for Option
Underlying Employees or Base Term(2)
Options in Price (1) Expiration __________________________________
Name Granted Fiscal Year ($/Share) Date 0%($) 5%($) 10%($)
___________________ _________ ___________ _________ __________ ______ _______ ______
Jeffrey H. Buchalter 40,000(3) 1.69% 15.46 9/28/2014 -- 388,908 985,570
725,000(3) 30.70% 13.54 12/22/2014 -- 6,173,544 15,644,973
750,000(3) 31.76% 6.95 5/12/2015 -- 3,278,113 8,307,382
Paul S. Davit 50,000(4) 2.12% 6.95 5/12/2014 -- 218,541 553,826
Ralph del Campo 50,000(5) 2.12% 6.95 5/12/2014 -- 218,541 553,826
Craig A. Tooman 125,000(6) 5.29% 13.08 1/5/2015 -- 1,028,243 2,605,769
50,000(6) 2.12% 6.95 5/12/2015 -- 218,541 553,826
50,000(6) 2.12% 5.73 6/10/2015 -- 179,991 456,025
(1) All options were granted at an exercise price that equaled or
exceeded the fair value of the Common Stock on the date of grant, as
determined by the last sale price as reported on the Nasdaq National
Market.
(2) The amounts set forth in the three columns represent hypothetical
gains that might be achieved by the optionees if the respective options are
exercised at the end of their terms. These gains are based on assumed rates
of stock price appreciation of 0%, 5% and 10% compounded annually from the
dates the respective options were granted. The 0% appreciation column is
included because the options were granted with exercise prices which
equaled or exceeded the market price of the underlying Common Stock on the
date of grant, and thus will have no value unless the Company's stock price
increases above the exercise prices.
(3) In September 2004, Mr. Buchalter was granted an option to purchase
40,000 shares of the Company's Common Stock for an exercise price of $15.46
per share upon his joining the Board of Directors. The vesting of these
options was accelerated and they became exercisable in April 2005 in
connection with the acceleration of vesting, in April 2005, of all out of
the money options to purchase shares of the Company's Common Stock. In
December 2004, Mr. Buchalter was granted 725,000 shares of the Company's
Common Stock at an exercise price of $13.54, pursuant to his employment
agreement. The vesting of these options was accelerated and they became
exercisable in April 2005 in connection with the acceleration of vesting,
in April 2005, of all out of the money options to purchase shares of the
Company's Common Stock. In May 2005, Mr. Buchalter was granted an option to
purchase 750,000 shares of the Company's Common Stock for an exercise price
of $6.95. The vesting of these options was accelerated and they became
exercisable in June 2005 in connection with the acceleration of vesting, in
June 2005, of all options held by Company officers.
12
(4) In May 2005, Mr. Davit was granted an option to purchase 50,000
shares of the Company's Common Stock for an exercise price of $6.95. The
vesting of these options was accelerated and they became exercisable in
June 2005 in connection with the acceleration of vesting, in June 2005, of
all options held by Company officers.
(5) In May 2005, Mr. del Campo was granted an option to purchase
50,000 shares of the Company's Common Stock for an exercise price of $6.95.
The vesting of these options was accelerated and they became exercisable in
June 2005 in connection with the acceleration of vesting, in June 2005, of
all options held by Company officers.
(6) In January 2005, Mr. Tooman was granted an option to purchase
125,000 shares of the Company's Common Stock for an exercise price of
$13.08 pursuant to his employment agreement. The vesting of these options
was accelerated and they became exercisable in April 2005 in connection
with the acceleration of vesting, in April 2005, of all out of the money
options to purchase shares of the Company's Common Stock. In May 2005, Mr.
Tooman was granted an option to purchase 50,000 shares of the Company's
Common stock at an exercise price of $6.95. The vesting of these options
was accelerated and they became exercisable in June 2005 in connection with
the acceleration of vesting, in June 2005, of all options held by Company
officers. In June 2005, Mr. Tooman was granted an option to purchase 50,000
shares of the Company's Common Stock at an exercise price of $5.73 pursuant
to his appointment as Executive Vice President, Finance and Chief Financial
Officer. The vesting of these options was accelerated and they became
exercisable in June 2005 in connection with the acceleration of vesting, in
June 2005, of all options held by Company officers.
The following table contains information concerning the grant of stock
options under the Company's stock option plans to the Named Executive
Officers during the six-month transition period ended December 31, 2005:
Individual Grants
-------------------------------------------------------
% of Total Potential Realizable Value at
Number of Options Assumed Annual Rates of Stock
Securities Granted to Exercise Price Appreciation for Option
Underlying Employees or Base Term(2)
Options in Price (1) Expiration __________________________________
Name Granted Six Month Period ($/Share) Date 0%($) 5%($) 10%($)
___________________ _________ ___________ _________ __________ ______ _______ ______
Jeffrey H. Buchalter 300,000(3) 31.30% 6.97 11/23/2015 - 1,315,019 3,332,515
Paul S. Davit 50,000(4) 5.22% 6.97 11/23/2015 - 219,170 555,419
Ralph del Campo 50,000(4) 5.22% 6.97 11/23/2015 - 219,170 555,419
Ivan D. Horak, M.D. 200,000(5) 20.87% 7.14 9/2/2015 - 898,062 2,275,864
35,000(4) 3.65% 6.97 11/23/2015 - 153,419 388,794
Craig A. Tooman 50,000(4) 5.22% 6.97 11/23/2015 - 219,170 555,419
(1) All options were granted at an exercise price that equaled or exceeded the
fair value of the Common Stock on the date of grant, as determined by the
last sale price as reported on the Nasdaq National Market.
(2) The amounts set forth in the three columns represent hypothetical gains
that might be achieved by the optionees if the respective options are
exercised at the end of their terms. These gains are based on assumed rates
of stock price appreciation of 0%, 5% and 10% compounded annually from the
dates the respective options were granted. The 0% appreciation column is
included because the options were granted with exercise prices which
equaled or exceeded the market price of the underlying Common Stock on the
date of grant, and thus will have no value unless the Company's stock price
increases above the exercise prices.
13
(3) Of the 300,000 shares granted, 96,000 vested on November 23, 2005, and
51,000 will vest on each of November 23, 2006, November 23, 2007, November
23, 2008 and November 23, 2009 so long as Mr. Buchalter remains an employee
of the Company on those dates.
(4) The option vests in four equal annual installments beginning on November
23, 2006.
(5) The option vests in four equal annual installments beginning on September
2, 2006.
OPTION EXERCISES DURING LAST FISCAL YEAR AND
SIX-MONTHS ENDED DECEMBER 31, 2005 AND PERIOD-END VALUES
The following table sets forth the information with respect to the Named
Executive Officers concerning the exercise of options during the fiscal year
ended June 30, 2005 and unexercised options held as of June 30, 2005.
Number of Securities Value of Unexercised
Underlying Unexercised In-the-Money Options
Options at FY-End (#) at FY-End ($)(1)
Shares Acquired Value --------------------- -------------------------
Name On Exercise (#) Realized($) Exercisable Unexercisable Exercisable Unexercisable
- ------------------ --------------- ------------ ------------ ------------ ------------ -------------
Jeffrey H. Buchalter - 1,515,000 - - -
-
Paul S. Davit - - 190,000 - - -
Ralph del Campo - - 210,000 - - -
Craig A. Tooman - - 225,000 - $37,500 -
(1) Based upon a market value of our common stock of $6.48 per share, as
determined by the last sale price as reported on the Nasdaq National Market
on June 30, 2005. If the exercise price is equal to or greater than such
last sale price, the option is deemed to have no value.
The following table sets forth the information with respect to the Named
Executive Officers concerning the exercise of options during the six-month
transition period ended December 31, 2005 and unexercised options held as of
December 31, 2005.
Number of Securities Value of Unexercised
Underlying Unexercised In-the-Money Options
Options at Six Month Period End (#) at Six Month Period End ($)(1)
Shares Acquired Value --------------------- -------------------------
Name On Exercise (#) Realized($) Exercisable Unexercisable Exercisable Unexercisable
- ------------------ --------------- ------------ ------------ ------------ ------------ -------------
Jeffrey H. Buchalter - - 1,611,000 204,000 $378,780 $87,720
Paul S. Davit - - 190,000 50,000 22,500 21,500
Ralph del Campo - - 210,000 50,000 22,500 21,500
Ivan D. Horak, M.D. - - - 235,000 - 67,050
Craig A. Tooman - - 225,000 50,000 106,000 21,500
(1) Based upon a market value of our common stock of $7.40 per share, as
determined by the last sale price as reported on the Nasdaq National Market
on December 30, 2005. If the exercise price is equal to or greater than
such last sale price, the option is deemed to have no value.
14
EMPLOYMENT AND SEPARATION AGREEMENTS
Jeffrey H. Buchalter
In December 2004, we entered into an employment agreement with Jeffrey H.
Buchalter, the Chairman of our Board of Directors, pursuant to which Mr.
Buchalter will serve as our Chief Executive Officer. The initial term of the
employment agreement will expire no earlier than December 31, 2009 and no later
than twelve months after either party gives notice to the other that such party
does not wish for the agreement to continue beyond such twelve-month period (a
"notice of non-renewal").
The agreement provides for a base salary of $550,000 per year and
participation in Enzon's bonus plan for management. Under the bonus plan, Mr.
Buchalter will be eligible to receive an annual performance-based cash bonus in
an amount between zero and 200% of base salary, based on individual and/or
corporate factors to be established and determined by the Board of Directors
each year. The annual target bonus is equal to 100% of Mr. Buchalter's base
salary. For the fiscal year ended June 30, 2005, Mr. Buchalter's bonus included
a guaranteed minimum bonus in the amount of $412,500.
Under the agreement, Mr. Buchalter was granted an option under our 2001
Incentive Stock Plan to purchase 725,000 shares of our Common Stock at a per
share exercise price of $13.54 (the last reported sale price of our common stock
on December 22, 2004, the date of grant). This option vested and became
exercisable in April 2005 in connection with the acceleration of vesting, in
April 2005, of all out of the money options to purchase shares of the Company's
Common Stock. Mr. Buchalter also received 75,000 shares of restricted Common
Stock, 22,500 of which shares will vest on each of the third and fourth
anniversaries of the date of grant and the remaining 30,000 of which shares will
vest on the fifth anniversary of the date of grant, provided Mr. Buchalter
remains employed as our Chief Executive Officer on each such date.
In the event Mr. Buchalter's employment is terminated by us without cause
(as defined in the employment agreement) or terminated by Mr. Buchalter for good
reason (as defined in the employment agreement), Mr. Buchalter will be entitled
to (i) a cash payment equal to any unpaid base salary through the date of
termination plus any earned bonus relating to the preceding fiscal year that
remains unpaid on the date of termination plus (ii) a lump sum cash payment
equal to four times his annual base salary plus a pro rata portion of his target
bonus for the period worked during the fiscal year in which the termination
occurs. In addition, we will reimburse Mr. Buchalter for any medical and dental
coverage available to him and his family for a period of up to 18 months
commencing on the date of termination, and all options and shares of restricted
stock described above that have not vested at the time of termination will vest
immediately upon termination.
If we experience a change of control (as defined in Mr. Buchalter's
employment agreement) and we terminate Mr. Buchalter's employment without cause
or he terminates his employment for good reason within the period commencing 90
days before such change of control and ending two years after the change of
control, Mr. Buchalter will be entitled to (i) a cash payment equal to any
unpaid base salary through the date of termination plus any earned bonus
relating to the preceding fiscal year that remains unpaid on the date of
termination plus (ii) a lump sum cash payment equal to six times his annual base
salary plus a pro rata portion of his target bonus for the period worked during
the fiscal year in which the termination occurs. In addition, we will reimburse
Mr. Buchalter for any medical and dental coverage available to him and his
family for a period of up to 18 months commencing on the date of termination.
Further, upon a change of control any of Mr. Buchalter's options to purchase
Common Stock and shares of restricted stock described above that have not vested
immediately prior to the effective date of the change of control shall vest at
such time.
If any payments or compensation received by Mr. Buchalter in connection
with a change of control are subject to an excise tax under Section 4999 of the
Internal Revenue Code, we will be obligated to make additional payments to Mr.
Buchalter equal to any such tax liability he may incur.
Mr. Buchalter's employment agreement requires him to maintain the
confidentiality of our proprietary information during the term of his agreement
and thereafter. Mr. Buchalter is precluded from competing with us during the
15
term of his employment agreement and for two years after his employment is
terminated (one year if the termination occurs pursuant to a notice of
nonrenewal from us).
Craig A. Tooman
In January 2005, we entered into an employment agreement with Craig A.
Tooman, pursuant to which Mr. Tooman was appointed our Executive Vice President
Strategic Planning and Corporate Communications. In June 2005, Mr. Tooman's
employment agreement was amended in connection with his appointment to the
position of Executive Vice President, Finance and Chief Financial Officer, while
retaining his duties and responsibilities as Executive Vice President, Strategic
Planning and Corporate Communications. The employment agreement, as amended,
will be effective until June 10, 2008, subject to automatic renewal for an
additional twenty-four months.
The amended agreement provides for a base salary of $365,000 per year and
participation in Enzon's bonus plan for management. Under the bonus plan, Mr.
Tooman will be eligible to receive an annual performance-based cash bonus in an
amount between zero and 82.5% of base salary, based on individual and/or
corporate factors to be established and determined by the Board of Directors
each year. The annual target bonus is equal to 50% of Mr. Tooman's base salary.
Within five days of the commencement of Mr. Tooman's employment, he received a
sign-on cash bonus in the amount of $125,000.
Pursuant to the agreement, Mr. Tooman was granted an option under our 2001
Incentive Stock Plan to purchase 125,000 shares of our Common Stock at a per
share exercise price of $13.08 (the last reported sale price of our common stock
on January 5, 2005, the date of grant). These options vested and became
exercisable in April 2005 in connection with the acceleration of vesting, in
April 2005, of all out of the money options to purchase shares of the Company's
Common Stock. Mr. Tooman also received 25,000 shares of restricted Common Stock,
7,500 of which shares will vest on each of the third and fourth anniversaries of
the date of grant and the remaining 10,000 shares will vest on the fifth
anniversary of the date of grant, provided Mr. Tooman remains employed by the
Company on each such date. In connection with Mr. Tooman's appointment to the
position of Executive Vice President Finance and Chief Financial Officer, he was
granted an option to purchase 50,000 shares of Common Stock at a per share
exercise price of $5.73 per share (the last reported sale price of our common
stock on June 10, 2005, the date of grant). The option vested and became
exercisable in June 2005 in connection with the acceleration of vesting, in June
2005, of all options held by Company officers.
In the event Mr. Tooman's employment is terminated by us without cause (as
defined in the employment agreement) or terminated by Mr. Tooman for good reason
(as defined in the employment agreement), Mr. Tooman will be entitled to (i) a
cash payment equal to any unpaid base salary through the date of termination
plus any earned bonus relating to the preceding fiscal year that remains unpaid
on the date of termination; (ii) a cash payment equal to one year of his base
salary plus a cash payment equal to the target bonus which would have been
payable for the fiscal year which commences immediately following the date of
his termination and (iii) a cash payment equal to a pro rata portion of his
target bonus for the fiscal year during which the termination occurs. In
addition, we will reimburse Mr. Tooman for any medical and dental coverage
available to him and his family for a period of up to 18 months commencing on
the date of termination, and all options and shares of restricted stock
described above that have not vested at the time of termination will vest
immediately upon termination.
If we experience a change of control (as defined in Mr. Tooman's employment
agreement) and we terminate Mr. Tooman's employment without cause or he
terminates his employment for good reason within the period commencing 90 days
before such change in control and ending one year after the change of control,
Mr. Tooman will be entitled to (i) a cash payment equal to any unpaid base
salary through the date of termination plus any earned bonus relating to the
preceding fiscal year that remains unpaid on the date of termination; (ii) a
cash payment equal to two times the sum of his base salary and target bonus for
the fiscal year in which the termination occurs and (iii) a cash payment equal
to a pro rata portion of his target bonus for the fiscal year during which the
termination occurs. In addition, we will reimburse Mr. Tooman for any medical
and dental coverage available to him and his family for a period of up to 18
months commencing on the date of termination. Further, upon a change of control
any of Mr. Tooman's options to purchase Common Stock and shares of restricted
Common Stock that have been granted to him, but not yet vested, prior to the
effective date of the change of control shall vest at such time.
16
Mr. Tooman's employment agreement requires him to maintain the
confidentiality of our proprietary information during the term of his agreement
and thereafter. Mr. Tooman is precluded from competing with us during the term
of his employment agreement and for one year after his employment is terminated.
Paul S. Davit
In May 2004, we entered into an amended and restated severance agreement
with Mr. Davit, then the Company's Senior Vice-President, Human Resources, the
initial term of which expired on December 31, 2004, with an automatic renewal
for an additional twelve months in January of each year, unless the Company
provides notice of non-renewal by September 30 of the preceding year.
Notwithstanding such notice by the Company not to extend, in the event that
there occurs, during the term, a change in control (as defined in Mr. Davit's
agreement), the agreement shall then continue in effect for a period of twelve
months beyond the date of such change of control.
In the event Mr. Davit's employment is terminated by us without cause (as
defined in Mr. Davit's agreement), or by Mr. Davit for good reason (as defined
in Mr. Davit's agreement) Mr. Davit will be entitled to: (i) a cash payment
equal to his annual base salary through the date of termination, and (ii) a cash
payment equal to the target bonus which would be payable for the fiscal year
during which such termination occurs. If we experience a change of control and
we terminate Mr. Davit's employment without cause or he terminates his
employment for good reason within the period commencing 90 days before such
change of control and ending one year after the change of control, Mr. Davit
will be entitled to (i) a cash payment equal to one and one half times his
annual base salary, (ii) a cash payment equal to one and one half times the
target bonus which would be payable for the fiscal year in which such
termination occurs, (iii) reimbursement for any medical and dental coverage
available to Mr. Davit and any family member for a period of up to eighteen
months commencing on the date of termination, (iv) all options to acquire shares
of the Company shall fully vest prior to the effective date of the change in
control, and any options not exercised prior to the effective date of the change
in control shall terminate as of the effective date, and (v) all shares of
restricted stock and/or restricted stock units will fully vest.
Upon entering into this agreement, Mr. Davit's change of control agreement
that had previously been in effect was terminated.
Ralph del Campo
In May 2004, we entered into an amended and restated severance agreement
with Mr. del Campo, then the Company's Senior Vice-President, Operations, the
initial term of which expired on December 31, 2004, with an automatic renewal
for an additional twelve months in January of each year, unless the Company
provides notice of non-renewal by September 30 of the preceding year.
Notwithstanding such notice by the Company not to extend, in the event that
there occurs, during the term, a change in control (as defined in Mr. del
Campo's agreement), the agreement shall then continue in effect for a period of
twelve months beyond the date of such change of control.
In the event Mr. del Campo's employment is terminated by us without cause
(as defined in Mr. del Campo's agreement), or by Mr. del Campo for good reason
(as defined in Mr. del Campo's agreement) Mr. del Campo will be entitled to: (i)
a cash payment equal to his annual base salary through the date of termination,
and (ii) a cash payment equal to the target bonus which would be payable for the
fiscal year during which such termination occurs. If we experience a change of
control and we terminate Mr. del Campo's employment without cause or he
terminates his employment for good reason within the period commencing 90 days
before such change of control and ending one year after the change of control,
Mr. del Campo will be entitled to (i) a cash payment equal to one and one half
times his annual base salary, (ii) a cash payment equal to one and one half
times the target bonus which would be payable for the fiscal year in which such
termination occurs (iii) reimbursement for any medical and dental coverage
available to Mr. del Campo and any family member for a period of up to eighteen
months commencing on the date of termination, (iv) all options to acquire shares
of the Company shall fully vest prior to the effective date of the change in
control, and any options not exercised prior to the effective date of the change
in control shall terminate as of the effective date, and (v) all shares of
restricted stock and/or restricted stock units will fully vest.
Upon entering into this agreement, Mr. del Campo's change of control
agreement that had previously been in effect was terminated.
17
Ivan D. Horak, M.D.
In September 2005, we entered into an employment agreement with Ivan D.
Horak, pursuant to which Dr. Horak was appointed our Executive Vice President
for Research and Development and Chief Scientific Officer. The employment
agreement will be effective until September 2, 2009, subject to automatic
renewal for an additional twenty-four months.
The agreement provides for a base salary of $425,000 per year and
participation in Enzon's bonus plan for management. Under the bonus plan, Dr.
Horak will be eligible to receive an annual performance-based cash bonus in an
amount between zero and 82.5% of base salary, based on individual and/or
corporate factors to be established and determined by the Board of Directors
each year. The annual target bonus is equal to 50% of Dr. Horak's base salary.
Within five days of the commencement of Dr. Horak's employment, he received a
sign-on cash bonus in the amount of $100,000.
Pursuant to the agreement, Dr. Horak was granted an option under our 2001
Incentive Stock Plan to purchase 200,000 shares of our Common Stock at a per
share exercise price of $7.14 (the last reported sale price of our common stock
on September 2, 2005, the date of grant). One-quarter of the options will vest
on each of the first four anniversaries of the grant. Dr. Horak also received
50,000 shares of restricted Common Stock, 15,000 of which shares will vest on
each of the third and fourth anniversaries of the date of grant and the
remaining 20,000 shares will vest on the fifth anniversary of the date of grant,
provided Dr. Horak remains employed as our Executive Vice President and Chief
Scientific Officer on each such date.
In the event Dr. Horak's employment is terminated by us without cause (as
defined in the employment agreement) or terminated by Dr. Horak for good reason
(as defined in the employment agreement), Dr. Horak will be entitled to (i) a
cash payment equal to any unpaid base salary through the date of termination
plus any earned bonus relating to the preceding fiscal year that remains unpaid
on the date of termination; (ii) a cash payment equal to one year of his base
salary plus a cash payment equal to the target bonus which would have been
payable for the fiscal year which commences immediately following the date of
his termination and (iii) a cash payment equal to a pro rata portion of his
target bonus for the fiscal year during which the termination occurs. In
addition, we will reimburse Dr. Horak for any medical and dental coverage
available to him and his family for a period of up to 18 months commencing on
the date of termination, and all options and shares of restricted stock
described above that have not vested at the time of termination will vest
immediately upon termination.
If we experience a change of control (as defined in the employment
agreement) and we terminate Dr. Horak's employment without cause or he
terminates his employment for good reason (as defined in the employment
agreement) within the period commencing 90 days before such change in control
and ending one year after the change of control, Dr. Horak will be entitled to
(i) a cash payment equal to any unpaid base salary through the date of
termination plus any earned bonus relating to the preceding fiscal year that
remains unpaid on the date of termination; (ii) a cash payment equal to two
times the sum of his base salary and target bonus for the fiscal year in which
the termination occurs and (iii) a cash payment equal to a pro rata portion of
his target bonus for the fiscal year during which the termination occurs. In
addition, we will reimburse Dr. Horak for any medical and dental coverage
available to him and his family for a period of up to 18 months commencing on
the date of termination. Further, upon a change of control any of Dr. Horak's
options to purchase Common Stock and shares of restricted Common Stock that have
been granted to him, but not yet vested, prior to the effective date of the
change of control shall vest at such time.
Dr. Horak's employment agreement requires him to maintain the
confidentiality of our proprietary information during the term of his agreement
and thereafter. Dr. Horak is precluded from competing with us during the term of
his employment agreement and for one year after his employment is terminated.
Kenneth J. Zuerblis
In April 2005, we entered into a separation agreement with Kenneth
Zuerblis. Under the separation agreement, Mr. Zuerblis voluntarily resigned as
Executive Vice President, Chief Financial Officer effective April 21, 2005.
Pursuant to the Separation Agreement, Mr. Zuerblis received a cash payment equal
to his annual base salary of $320,000, a cash payment equal to the pro rata
amount of his annual target bonus for the fiscal year 2005 (which was 50% of his
base salary) or $133,000, and a cash payment equal to his annual target bonus
18
for fiscal year 2006 or $160,000. All options to acquire shares in the Company
held by Mr. Zuerblis as of the separation date vested and shall remain
exercisable after such date in accordance with the terms of the relevant plans
and granting instruments (to the extent any provision of this agreement
conflicts with any provision of any stock option plan or agreement between the
Company and Mr. Zuerblis, the provisions of the Separation Agreement shall take
precedence). In addition, the period of time he has to exercise certain of his
options was extended to 18 months; the vesting of some of his options and
restricted stock were accelerated; and he will be reimbursed for his medical
insurance premiums for up to 36 months.
Dr. Ulrich Grau
In November 2004, we entered into a Separation Agreement with Dr. Grau. Dr.
Grau voluntarily resigned as Executive Vice President and Chief Scientific
Officer effective March 31, 2005. Pursuant to the Separation Agreement, Dr.
Grau's received a cash payment equal to nine months of his base salary or
$334,000 as well as a cash payment of 90% his annual target bonus for fiscal
year 2005 (50% of base salary) payable in August 2005 of $200,250.
At the time of Dr. Grau's resignation, none of the shares of restricted
stock or restricted stock units granted had vested. At that time, all unvested
shares of restricted Common Stock and all unvested options to purchase Common
Stock were canceled. All options to purchase Common Stock granted under the
Company's Non-Qualified Stock Plan that had vested by his resignation date
remained outstanding and exercisable until October 2005. All options to purchase
Common Stock under the Company's Incentive Stock Plan that had vested by his
resignation date shall remain outstanding and exercisable until March 2006.
Dr. Grau's separation agreement requires him to comply with a non-compete
covenant of up to two years with respect to certain technologies and compounds.
Share Ownership Guidelines for Senior Management
In July 2005, the Board of Directors approved share ownership guidelines
for our senior management. These guidelines are applicable to the Chief
Executive Officer, Executive Officers and other Vice President level employees.
Under the share ownership guidelines, members of senior management are
encouraged to acquire and maintain share holdings in the Company's Common Stock
in amounts expressed as a multiple of base salary. The guidelines provide for a
four-year window within which the share ownership level is to be achieved. These
ownership guidelines are designed to further align executive ownership,
long-term strategic thinking and compensation programs to Company performance
and the interests of its stockholders.
The following multiples of base salary apply:
o three times base salary for the Chief Executive Officer;
o two times base salary for Executive Officers; and
o two times base salary for other Vice President level employees.
The following will be counted in determining share ownership:
o shares purchased on the open market;
o shares owned jointly with or separately by spouse and/or children;
o shares held by the individual in the Company's 401(k) plan;
o shares obtained through stock option exercise;
o restricted stock or restricted stock units; and
o vested and "in the money" unexercised options, provided that these
shares may not exceed 50% of the requirement total.
19
Executive Deferred Compensation Plan
The Executive Deferred Compensation Plan (the "Plan") provides a select
group of management or highly compensated employees of the Company with the
opportunity to defer the receipt of certain cash compensation. Effective January
1, 2005, the Plan was amended and restated to comply with the deferred
compensation provisions in the American Jobs Creation Act of 2004, and the
restated Plan applies to all deferrals which relate entirely to services
performed on or before December 31, 2004 (i.e., with respect to compensation
that was earned and vested as of December 31, 2004) and deferrals which relate
all or in part to services performed on or after January 1, 2005.
The obligations of the Company under the Plan (the "Deferred Compensation
Obligations") shall be that of an unfunded and unsecured promise of the Company
to pay money in the future to participating eligible employees (the
"Participants") in accordance with the terms of the Plan from the general assets
of the Company, and will rank pari passu with other unsecured and unsubordinated
indebtedness of the Company from time to time outstanding.
Each Participant may elect to defer under the Plan all or a portion of his
or her base salary and/or annual incentive compensation that may otherwise be
payable in a calendar year. In addition, the committee administering the Plan
may, in its sole discretion, award non-elective deferred compensation to a
Participant. Any credit of non-elective deferred compensation will vest in
accordance with the schedule determined by the committee and shall be
distributed in a manner consistent with the election last made by the particular
Participant.
A Participant's compensation deferrals are credited to the Participant's
bookkeeping account ("Account") maintained under the Plan. A Participant shall
allocate his or her Account among the deemed investment options available under
the Plan from time to time. Amounts credited to Participants' Accounts for each
year are adjusted for earnings or losses based on the investment options elected
by the Participant. The Company is not obligated to actually invest any deferred
amounts in those investment options. Each Participant's Account is credited on a
daily basis with a deemed rate of interest and/or earnings or losses depending
upon the investment performance of the deemed investment option.
The Participant may generally elect the time and manner of payment of the
Deferred Compensation Obligations. At the election of the Participant, payment
of the Deferred Compensation Obligations may be made in a lump sum or in
substantially equal annual installments (subject to a maximum of ten (10) annual
installments). The time for payment elected by the Participant shall be a date
certain at the time of election or the date of the Participant's separation from
service, provided that such specified date shall actually occur on or prior to
the Participant's separation from service, disability or death or a change in
control of the Company. In the event of a change in control of the Company in
accordance with the terms of the Plan, payments will be made in the form of a
lump sum.
Neither a Participant, nor any other person, shall have any right to
commute, sell, assign, transfer, pledge, anticipate, mortgage or otherwise
encumber, transfer, hypothecate or convey any amounts payable under the Plan in
advance of the actual receipt of such amounts.
The Deferred Compensation Obligations are not subject to redemption, in
whole or in part, prior to the individual payment dates selected by the
Participants, except that Participants may withdraw all or a portion of the
value of their Plan accounts under certain specified circumstances and certain
mandatory lump sum distributions may be made. The Company reserves the right to
amend or terminate the Plan at any time, provided that, except as otherwise
provided in the Plan, no amendment shall decrease the benefits to a Participant
on compensation deferred prior to the date of the amendment without the consent
of the Participant.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Ownership of and transactions in the Company's Common Stock by executive
officers and directors of the Company and owners of 10% or more of the Company's
outstanding Common Stock are required to be reported to the Securities and
Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of
1934, as amended. Based solely on the Company's review of such reports and
written representations from certain reporting persons, during the six-month
transition period ended December 31, 2005, all such reports were filed in a
20
timely manner except as follows: Messrs. Ando, Classon, LeBuhn, Micati, Renfro,
Salisbury and Dr. Dixon were late in filing Form 4s relating to restricted stock
units granted to each of them on July 1, 2005. The Form 4s were subsequently
filed on September 8, 2005.
REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
During the fiscal year ended June 30, 2005 and the six-month transition
period ended December 31, 2005, the Compensation Committee of the Board of
Directors consisted of at least three non-employee directors all of whom are
independent under Rule 4200(a)(15) of the NASD Listing Standards. The
Compensation Committee determines all compensation paid or awarded to the
Company's executive officers, including the Named Executive Officers in the
Summary Compensation Table.
Compensation Philosophy
The philosophy of our compensation programs is to enhance the Company's
performance and stockholder value by aligning the financial interests of the
Company's senior managers with those of its stockholders, while keeping the
overall compensation package competitive. The compensation package for officers
includes a number of components. The package is designed to align individual
compensation with the short-term and long-term performance of the Company and is
based on the following principles:
o Pay for the achievement of business and strategic objectives, as
measured by the Company's financial and operating performance, as well
as individual strategic, management and development goals.
o Pay competitively, with compensation set at levels that will attract
and retain key employees. The Company regularly reviews compensation
surveys of companies in the biopharmaceutical industry and sets
compensation levels based on the results of these reviews.
o Align compensation with the interests of stockholders through equity.
The compensation package for each of the Named Executive Officers as well
as other officers who are members of the Company's executive staff consists of
four elements: (1) base salary, (2) annual performance-based incentive, (3)
stock incentive programs, and (4) various other benefits. More specific
information on each of these elements follows.
Base Salary
The Compensation Committee aims to set base salaries at levels that are
competitive with those paid to senior executives with comparable qualifications,
experience and responsibilities at other companies in the pharmaceutical and
biotechnology industries, including a selected subset of companies included in
the Nasdaq Biotechnology Index line of the stock performance graph that appears
in this proxy statement. The Compensation Committee believes that this is
necessary to attract and retain the executive talent required to lead the
Company, since the Company competes with a large number of companies in the
biopharmaceutical industry, including large pharmaceutical companies, for
executive talent. Salaries are reviewed annually and in connection with
promotions. Industry, peer group and national survey results are considered in
making salary determinations to align the Company's pay practices with other
companies in the pharmaceutical and biotechnology industries. In addition to
survey results, individual job performance is also considered in setting
salaries. The Chief Executive Officer conducts performance reviews of members of
executive management and makes recommendations to the Compensation Committee on
salary, including salary increases, based on his judgment of the individual's
performance. The Compensation Committee reviews these recommendations
independently and approves, with any modifications it considers appropriate, the
annual salary and salary increases.
In connection with the Company's change in fiscal year end from June 30 to
December 31, the Compensation Committee reviewed base salaries following both
the fiscal year ended June 30, 2005 and the six-month transition period ended
December 31, 2005, and effected salary increases at each time.
21
Annual Performance Based Incentive Compensation
The Company maintains an incentive program that provides an opportunity for
officers and employees to earn an incentive based upon the performance of both
the Company and the individual (the "Performance Incentive Program"). The
incentive potential is stated as a percentage of the officer's and employee's
base salary and varies by position. Financial and individual performance goals
are set at the start of the fiscal year and are based on business criteria
specified in this program. Actual incentives are calculated at the end of the
fiscal year based on goal performance. All executive management had the same
Company goals for the periods covered by this report. Other goals and weightings
for each participant varied, depending on the participant's position and areas
of responsibility and the participant's effect on the Company's performance.
In connection with the Company's change in fiscal year end from June 30 to
December 31, the Compensation Committee calculated performance incentives
following both the fiscal year ended June 30, 2005 and the six-month transition
period ended December 31, 2005, and the Company paid those performance
incentives at each time.
Stock Incentive Programs
The Compensation Committee believes that stock incentive programs such as
stock options directly link the amounts earned by officers with the amount of
appreciation realized by the Company's stockholders. Restricted stock,
restricted stock units and stock options also serve as a critical retention
incentive. Stock incentive programs have always been viewed as a major means to
attract and retain highly qualified executives and key personnel and have always
been a major component of the compensation package, consistent with practices
throughout the pharmaceutical and biotechnology industries. The Company's stock
incentive programs are structured to encourage key employees to continue in the
employ of the Company and motivate performance that will meet the long-term
expectations of stockholders. In determining the size of any option or
restricted stock or restricted stock unit award ("Incentive Stock Grants"), the
Compensation Committee considers the individual's past performance and potential
and the position held by the individual.
The Compensation Committee generally considers and makes incentive stock
grants to officers and all other employees once a year. Incentive Stock Grants
may also be granted at other times during the year in connection with promotions
or for new hires or as special performance awards. Option grants to members of
executive management are made under the Stock Option Plans with the exercise
price equal to the last reported sale price of the Company's Common Stock on the
date of grant and expire up to ten years after the date of the grant. Vesting on
most incentive stock grants occurs over a four to five year period, which is
designed to encourage retention.
Other Benefits
Executive staff members participate in various medical, dental, life,
disability and benefit programs that are generally made available to all
salaried employees.
CEO Compensation
The compensation of Mr. Buchalter, the Company's President and Chief
Executive Officer, was initially established by the full Board of Directors in
connection with his appointment as President and Chief Executive Officer in
December 2004. In establishing his compensation, the Board took into
consideration Mr. Buchalter's extensive prior experience and credentials as a
chief executive officer and senior executive in the pharmaceutical industry, as
well as Mr. Buchalter's qualifications to address the challenges facing Enzon at
that time and the limited market of candidates possessing those necessary
qualifications. The Board reviewed and considered the compensation of chief
executive officers at comparable companies and also received guidance from an
executive search firm engaged by the Company in connection with the recruitment
of a chief executive officer based on such firm's knowledge of the competitive
marketplace for chief executive officers and the relative compensation of chief
executive officers at comparable companies. The Board determined that Mr.
Buchalter's compensation, as so established, was commensurate with his
experience and credentials and reasonable relative to the competitive
marketplace for chief executive officers.
22
For the fiscal year ended June 30, 2005 and the six-month transition period
ended December 31, 2005, Mr. Buchalter was awarded performance bonuses in
accordance with his employment agreement (including a guaranteed minimum bonus
for the fiscal year ended June 30, 2005) and based on the Compensation
Committee's evaluation of his individual performance and the Company's
performance during each of those periods.
THE COMPENSATION COMMITTEE
Goran A. Ando, Chairman
Rolf A. Classon
Victor P. Micati
23
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
In addition to the agreements described in the section "Employment and
Separation Agreements" above, the Company entered into the following
relationships:
Craig A. Tooman received benefits in connection with his appointment as
Executive Vice President, Strategic Planning and Corporate Communications. We
are party to a relocation services agreement with an independent third party
(the "Provider") pursuant to which, in accordance with our relocation policy, in
March 2005 the Provider purchased Mr. Tooman's residence at a purchase price
calculated using the average of two independent appraisals of the property (the
"Purchase Price"). Mr. Tooman was paid $324,388 in connection with the
transaction which amount represented Mr. Tooman's equity in the property. Under
the relocation services agreement, we reimbursed the Provider for the equity
component of the Purchase Price and the related closing costs. We are
responsible for a $2,500 service fee to the Provider as well as carrying and
sales costs that the Provider incurs in connection with selling the property. On
October 26, 2005, the property was sold for less than the Purchase Price, and
the Company reimbursed the Provider for $162,689, which includes the amount of
the deficiency, closing and carrying costs.
Jeffrey H. Buchalter received relocation benefits in connection with his
appointment as Chief Executive Officer. The Company is administering these
benefits through a relocation services agreement with an independent third party
(the "Provider") pursuant to which, in accordance with Enzon's relocation
policy, in September 2005 the Provider purchased Mr. Buchalter's residence at a
purchase price calculated using the average of two independent appraisals of the
property (the "Purchase Price"). Mr. Buchalter was paid $412,384 in connection
with the transaction which amount represented Mr. Buchalter's equity in the
property. Under the relocation services agreement, the Company reimbursed the
Provider for the equity component of the Purchase Price and the related closing
costs. The Company is responsible for a $2,500 service fee to the Provider as
well as carrying and sales costs that the Provider incurs in connection with
selling the property. The Company will receive the net proceeds from the resale
of the property, and, if the property is sold for less than the Purchase Price,
it is responsible for reimbursing the Provider for the amount of the deficiency.
24
REPORT OF THE FINANCE AND AUDIT COMMITTEE OF
THE BOARD OF DIRECTORS
The Company's Finance and Audit Committee consists of four independent
members of the Board of Directors as defined in Rule 4200(a)(15) of the National
Association of Securities Dealers' listing standards. The Board of Directors
adopted a written charter for the Finance and Audit Committee on June 7, 2000
and the Finance and Audit Committee reviewed and revised such charter on
September 11, 2002 and on March 15, 2006. The charter of the Finance and Audit
Committee as amended is attached to this Proxy Statement as Appendix A.
The primary purpose of the Finance and Audit Committee is to assist the
Board of Directors in its oversight responsibilities by monitoring the integrity
of the Company's financial reporting process and financial statements, the
systems of internal controls and controls over financial reporting, the
compliance by the Company with legal and regulatory requirements, and the
performance and independence of the Company's independent auditors. Management
of the Company is responsible for the preparation, presentation and integrity of
the Company's financial statements and for the maintenance of policies and
internal controls necessary to assure compliance with accounting standards and
applicable laws and regulations. The independent auditors are responsible for
planning and conducting an audit of the Company's consolidated financial
statements, reviews of the Company's quarterly financial statements and
performing such other procedures required by applicable Statements of Auditing
Standards or requested by the Committee. The independent auditors audit the
annual financial statements prepared by management, express an opinion as to
whether those financial statements present fairly, in all material respects, the
financial position, results of operations and cash flows of the company in
conformity with accounting principles generally accepted in the United States
and discuss with us their independence and any other matters they are required
to discuss with us or that they believe should be raised with us. We oversee
these processes, although we must rely on the information provided to us and on
the representations made by management and the independent auditors.
The Finance and Audit Committee has reviewed and discussed the audited
financial statements for the fiscal year ended June 30, 2005 and the six-month
transition period ended December 31, 2005 with management. Furthermore, the
Finance and Audit Committee has discussed with the Company's independent
auditors, KPMG LLP, the matters required to be discussed by Statement of
Auditing Standards No. 61. Also, the Finance and Audit Committee has received
the written disclosures and letter from KPMG required by Independence Standards
Board Standard No. 1 and has discussed with KPMG such auditing firm's
independence. Based on these reviews and discussions the Finance and Audit
Committee recommended that the audited financial statements be included in the
Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2005 and
the Company's Transition Report on Form 10-K for the six-month transition period
ended December 31, 2005, the last fiscal periods for filing such reports with
the U.S. Securities and Exchange Commission.
THE FINANCE AND AUDIT COMMITTEE
Robert C. Salisbury, Chairman
Rolf A. Classon
Robert LeBuhn
Phillip M. Renfro
25
STOCKHOLDER RETURN PERFORMANCE GRAPH
The graph below summarizes the total cumulative return experienced by the
Company's stockholders from June 29, 2001 through December 31, 2005, compared to
the Nasdaq National Market-US Index and the Company's Peer Group index, the
Nasdaq Biotechnology Index. The changes for the periods shown in the graph and
table below are based on the assumption that $100 had been invested in the
Company's Common Stock, including the reinvestment of dividends, and in each
index below on June 29, 2001.
Comparison of 54 Month Cumulative Total Return Among Enzon Pharmaceuticals,
Inc., The Nasdaq National Market Index and Peer Groups
[GRAPHIC OMITTED] Cumulative Total Return
-------- --------- --------- --------- --------- ---------
6/01 6/02 6/03 6/04 6/05 12/05
ENZON PHARMACEUTICALS, INC. 100.00 40.19 20.08 20.42 10.37 11.84
NASDAQ STOCK MARKET (U.S.) 100.00 70.23 78.15 98.60 99.30 107.39
NASDAQ BIOTECHNOLOGY 100.00 49.74 49.07 57.05 62.21 76.71
26
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information as of April 14, 2006
concerning stock ownership of all persons known by the Company to own
beneficially 5% or more of the outstanding shares of the Company's voting stock,
each director, each current executive officer named in the Summary Compensation
Table and all directors and current executive officers of the Company as a
group:
Amount and Nature
of Beneficial Percentage of Voting
Name and Address of Beneficial Owner or Identity of Group(1) Ownership(2) Stock Outstanding(3)
- -------------------------------------------------------------- ---------------- --------------------
Jeffrey H. Buchalter 1,632,078(4) 3.6%
Dr. Goran A. Ando 35,522(5) *
Rolf A. Classon 95,598(6) *
Dr. Rosina B. Dixon 179,607(7) *
Robert LeBuhn 126,134(8) *
Victor P. Micati 35,522(9) *
Phillip M. Renfro 20,632(10) *
Robert C. Salisbury 8,667(11) *
Paul S. Davit 196,800(12) *
Ralph del Campo 210,101(13) *
Dr. Ivan D. Horak 8,500 *
Craig A. Tooman 226,000(14) *
Pequot Capital Management, Inc., 500 Nyala Farm Road, Westport, CT 5,068,000(15) 11.6
06880
Group comprised of Barclay Global Investors, N.A., Barclay Global 3,743,463(16) 8.6
Fund Advisors, Barclays Global Investors, Ltd, and Barclays Global
Investors Japan Trust and Banking Company Limited, 45 Fremont
Street, San Francisco, CA 94105
Group comprised of OrbiMed Advisors LLC, OrbiMed Capital LLC and 2,740,500(17) 6.3
Samual D. Isaly, 767 Third Avenue, New York, NY 10017
All Executive Officers and Directors as a group (12 persons) 2,775,161(18) 6.0
* Less than one percent
(1) The address of all current executive officers and directors listed above is
in the care of the Company.
(2) All shares listed are Common Stock. Except as discussed below, none of
these shares are subject to rights to acquire beneficial ownership, as
specified in Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, as
amended, and the beneficial owner has sole voting and investment power,
subject to community property laws where applicable.
(3) Based on 43,746,855 shares of Common Stock which were issued and
outstanding as of April 14, 2006. Each share of Common Stock is entitled to
one vote. The percentage of voting stock outstanding for each stockholder
is calculated by dividing (i) the number of shares of Common Stock deemed
to be beneficially held by such stockholder as of April 14, 2006 by (ii)
the sum of (A) the number of shares of Common Stock outstanding as of April
14, 2006 plus (B) the number of shares of Common Stock issuable upon
exercise of options held by such stockholder which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006.
27
(4) Includes (i) 1,611,000 shares subject to options which were exercisable as
of April 14, 2006 or which will become exercisable within 60 days after
April 14, 2006 and (ii) 1,078 shares of restricted stock which vested.
(5) Includes (i) 35,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006 and (ii) 522 shares of restricted stock which vested.
(6) Includes (i) 85,000 shares subject to options which were exercisable as of
April 14, 2006 or will become exercisable within 60 days after April 14,
2006 and (ii) 663 shares of restricted stock which vested.
(7) Includes (i) 125,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006, (ii) 663 shares of restricted stock that vested and (ii) 500
shares held by Dr. Dixon's husband. Dr. Dixon disclaims beneficial
ownership as to shares held by her husband.
(8) Includes (i) 85,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006 and (ii) 663 shares of restricted stock that vested.
(9) Includes (i) 35,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006 and (ii) 522 shares of restricted stock which vested.
(10) Includes (i) 20,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006 and (ii) 632 shares of restricted stock which vested.
(11) Includes 6,667 shares subject to options which were exercisable as of April
14, 2006.
(12) Includes (i) 190,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006. (ii) 300 shares held through Mr. Davit's 401(k) account.
(13) Includes 210,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006. (ii) 101 shares held through Mr. del Campo's 401(k) account.
(14)Includes 225,000 shares subject to options which were exercisable as of
April 14, 2006 or which will become exercisable within 60 days after April
14, 2006.
(15) Information concerning stock ownership was obtained from Schedule 13G filed
with the Securities and Exchange Commission on February 14, 2006.
(16) Information concerning stock ownership was obtained from Schedule 13G filed
with the Securities and Exchange Commission on January 26, 2006.
(17) Information concerning stock ownership was obtained from Schedule 13G filed
with the Securities and Exchange Commission on February 2, 2006.
(18) Includes all shares owned beneficially by the directors and executive
officers named in the Summary Compensation Table.
28
PROPOSAL NO. 2 - APPROVAL OF AMENDMENT TO THE 2001 INCENTIVE STOCK PLAN
General
The Board believes that in order to attract and retain qualified
executives, employees and board members it is essential to offer significant
potential rewards based upon the Company's success through the issuance of stock
options, restricted stock grants and other stock-based awards. The 2001
Incentive Stock Plan, which was approved by our stockholders in December 2001
and amended with stockholder approval in December 2003, provides for the grant
of stock options and other stock-based awards to employees, officers,
consultants, independent contractors and directors providing services to Enzon
and its subsidiaries as determined by the Board of Directors or by a committee
of directors designated by the Board of Directors to administer the 2001
Incentive Stock Plan. The amendment to the Plan increasing the shares of Common
Stock authorized for issuance presented herein to the stockholders for their
approval is designed to assist the Company in accomplishing this goal. Of the
6,000,000 shares currently authorized for issuance under the 2001 Stock
Incentive Plan and the 7,900,000 shares currently authorized for issuance under
the Company's Non-Qualified Stock Option Plan, at April 6, 2006, ______________
shares in the aggregate remained available for future grants.
Since October 2003, the number of persons eligible to participate under the
2001 Incentive Stock Plan has remained relatively constant, creating a continued
need for our stock options and restricted stock grants. The current shares
available under the 2001 Incentive Stock Plan have declined to a point whereby
we will soon not be able to offer future awards without additional shares.
Therefore, an amendment to the 2001 Incentive Stock Plan proposed herein
provides for the increase in the number of shares of common stock available
thereunder by 4,000,000 to an aggregate of 10,000,000 shares.
In order to facilitate approval of Proposal No. 2 and assuage any
stockholder concerns regarding the number of options, restricted stock awards or
restricted stock units awards the Company intends to grant in a given year, the
Board of Directors of the Company commits to the Company's stockholders that for
the next three fiscal years it will not grant in a fiscal year a number of
shares subject to options, restricted stock awards or restricted stock units
awards to employees (whether under the 1987 Non-Qualified Stock Option Plan, the
2001 Incentive Stock Plan or other plans not approved by stockholders) greater
than 5.57% of the number of shares of the Company's Common Stock that the
Company believes will be outstanding at the end of the same fiscal year. For
purposes of calculating the number of shares granted in a year, restricted stock
awards or restricted stock units awards will count as equivalent to (i) 1.5
option shares if the Company's annual stock price volatility is 53% or higher,
(ii) two option shares if the Company's annual stock price volatility is between
25% and 52%, and (iii) four option shares if the Company's annual stock price
volatility is less than 25%.
The following summary of the 2001 Incentive Stock Plan, as it is proposed
to be amended, is qualified in its entirety by reference to the full text of the
2001 Incentive Stock Plan, as it is proposed to be amended, which is attached to
this Proxy Statement as Appendix B.
On December 17, 2002 and December 20, 2004, Enzon filed registration
statements on Form S-8 covering the securities to be issued under the 2001
Incentive Stock Plan. If this Proposal No. 2 is approved by the stockholders,
Enzon intends to file a Form S-8 covering the additional securities to be issued
under the 2001 Incentive Stock Plan.
Summary of the 2001 Incentive Stock Plan
Purpose. The purpose of the 2001 Incentive Stock Plan is to promote the
interests of Enzon and its stockholders by aiding Enzon in attracting and
retaining employees, officers, consultants, independent contractors and
non-employee directors capable of contributing to the future success of Enzon,
to offer such persons incentives to put forth maximum efforts for the success of
Enzon's business and to afford such persons an opportunity to acquire a
proprietary interest in Enzon. The Compensation Committee believes that stock
based compensation directly links the amount earned by employees with the amount
of appreciation realized by the Company's stockholders.
Administration. The Compensation Committee has been designated by the Board
of Directors to administer the 2001 Incentive Stock Plan. The Compensation
Committee will have full power and authority to determine when and to whom
29
awards will be granted and the type, amount, form of payment and other terms and
conditions of each award, consistent with the provisions of the 2001 Incentive
Stock Plan. Subject to the provisions of the 2001 Incentive Stock Plan, the
Compensation Committee may amend or waive the terms and conditions of an
outstanding award. The Compensation Committee will have full authority to
interpret the 2001 Incentive Stock Plan and establish rules and regulations for
the administration of the 2001 Incentive Stock Plan. The Compensation Committee
may delegate to one or more directors or officers, or a committee of directors
or officers, or the Board of Directors may exercise, the Compensation
Committee's powers and duties under the 2001 Incentive Stock Plan.
Eligibility. Any employee, officer, consultant, independent contractor or
director providing services to Enzon and its subsidiaries will be eligible to be
selected by the Compensation Committee to receive awards under the 2001
Incentive Stock Plan. As of April 6, 2006, there were approximately ______
persons who were eligible as a class to be selected by the Compensation
Committee to receive awards under the 2001 Incentive Stock Plan.
Number of Shares. As it is proposed to be amended, the 2001 Incentive Stock
Plan would provide for the issuance of up to 10,000,000 shares of Common Stock,
subject to adjustment in the event of a stock dividend or other distribution,
recapitalization, stock split, reverse stock split, reorganization, merger,
consolidation, split-up, spin-off, combination, issuance of warrants or other
rights to purchase shares of Common Stock or other securities of Enzon to all
holders of Common Stock pro rata whether as a dividend or otherwise or other
similar changes in the corporate structure or stock of Enzon. Currently, the
maximum number of shares available for issuance under the 2001 Incentive Stock
Plan is 6,000,000. Shares of Common Stock subject to awards under the 2001
Incentive Stock Plan which are not used or are forfeited because the terms and
conditions of the awards are not met, or because the award terminates without
delivery of any shares, may again be used for awards (other than Incentive Stock
Options) under the 2001 Incentive Stock Plan. Shares of Common Stock used by a
participant as full or partial payment to Enzon of the purchase price relating
to an award, or in connection with the satisfaction of tax obligations relating
to an award, will also be available for awards under the 2001 Incentive Stock
Plan. The shares of Common Stock issued under the 2001 Incentive Stock Plan may
be authorized but unissued shares or shares acquired on the open market or
otherwise. The last reported sale price of Enzon's Common Stock as reported by
the Nasdaq National Market on April 6, 2006, was $____. No participant may be
granted stock options and any other award, the value of which is based solely on
an increase in the price of the Common Stock, of more than 1,000,000 shares in
the aggregate in any calendar year.
Types of Awards and Certain Terms and Conditions. The types of awards that
may be granted under the 2001 Incentive Stock Plan are stock options, stock
appreciation rights, restricted stock, restricted stock units, performance
awards, dividend equivalents, other stock grants, other stock-based awards and
any combination thereof. The 2001 Incentive Stock Plan provides that all awards
are to be evidenced by written agreements containing the terms and conditions of
the awards. The Compensation Committee may not amend or discontinue any
outstanding award without the consent of the holder of the award if such action
would adversely affect the rights of the holder. Except as provided by the 2001
Incentive Stock Plan, awards (other than Other Stock Grants, as defined in the
2001 Incentive Stock Plan) will not be transferable other than (1) to family
members (as determined by the Compensation Committee), (2) by will or (3) by the
laws of descent and distribution. During the lifetime of a participant, an award
may be exercised only by the participant to whom such award is granted or a
permitted assignee. Awards may be granted for no cash consideration or for any
cash or other consideration as may be determined by the Compensation Committee
or required by law. Generally, the consideration to be received by Enzon for the
grant of awards under the 2001 Incentive Stock Plan will be the participant's
past, present or expected future contributions to Enzon.
Stock Options. Incentive stock options meeting the requirements of Section
422 of the Internal Revenue Code ("Incentive Stock Options") and non-qualified
options may be granted under the 2001 Incentive Stock Plan. The Compensation
Committee will determine the exercise price of any option granted under the 2001
Incentive Stock Plan, provided however that the exercise price of options will
not be less than the fair market value of the Common Stock on the date of grant.
The term of the option will be determined by the Compensation Committee, but
shall in no event exceed 10 years from the date on which such option was
granted. Stock options will be exercisable at such times as the Compensation
Committee determines. Stock options may be exercised in whole or in part by
payment in full of the exercise price in cash or such other form of
30
consideration as the Compensation Committee may specify, including delivery of
shares of Common Stock having a fair market value on the date of exercise equal
to the exercise price. The Compensation Committee may grant reload options when
a participant pays the exercise price or tax withholding upon exercise of an
option by using shares of Common Stock. The reload option would be for that
number of shares surrendered or withheld.
Stock Appreciation Rights. The Compensation Committee may grant stock
appreciation rights exercisable at such times and subject to such conditions or
restrictions as the Compensation Committee may determine. Upon exercise of a
stock appreciation right by a holder, the holder is entitled to receive the
excess of the fair market value of one share of Common Stock on the date of
exercise over the fair market value of one share of Common Stock on the date of
grant. The payment may be made in cash or shares of Common Stock, or other form
of payment, as determined by the Compensation Committee.
Restricted Stock and Restricted Stock Units. The Compensation Committee may
grant shares of restricted stock and restricted stock units subject to such
restrictions and terms and conditions as the Compensation Committee may impose.
Shares of restricted stock granted under the 2001 Incentive Stock Plan will be
evidenced by stock certificates, which will be held by Enzon, and the
Compensation Committee may, in its discretion, grant voting and dividend rights
with respect to such shares. No shares of stock will be issued at the time of
award of restricted stock units. A restricted stock unit will have a value equal
to the fair market value of one share of Common Stock and may include, if so
determined by the Compensation Committee, the value of any dividends or other
rights or property received by stockholders after the date of grant of the
restricted stock unit. The Compensation Committee has the right to waive any
vesting requirements or to accelerate the vesting of restricted stock or
restricted stock units. The maximum number of shares of restricted stock and
restricted stock units that the Compensation Committee is permitted to grant
under the 2001 Incentive Stock Plan is 50% of the total number of shares
available for issuance pursuant to all awards under the 2001 Incentive Stock
Plan.
Dividend Equivalents. The Compensation Committee may grant dividend
equivalents under which a holder shall be entitled to receive payments, in cash,
Common Stock, other securities or other property, equivalent to the amount of
cash dividend paid by Enzon to holders of Common Stock with respect to a number
of shares of Common Stock determined by the Compensation Committee. The
Compensation Committee will determine the terms and conditions of such dividend
equivalents.
Performance Awards. A performance award will entitle the holder to receive
payments upon the achievement of specified performance goals. The Compensation
Committee will determine the terms and conditions of a performance award,
including the performance goals to be achieved during the performance period,
the length of the performance period and the amount and form of payment of the
performance award. A performance award may be denominated or payable in cash,
shares of stock or other securities, or other awards or property.
Other Stock Grants. The Compensation Committee may otherwise grant shares
of Common Stock as are deemed by the Compensation Committee to be consistent
with the purpose of the 2001 Incentive Stock Plan. The Compensation Committee
will determine the terms and conditions of such other stock grant.
Other Stock-Based Awards. The Compensation Committee may grant other awards
denominated or payable in, valued by reference to, or otherwise based on or
related to shares of Common Stock as are deemed by the Compensation Committee to
be consistent with the purpose of the 2001 Incentive Stock Plan. The
Compensation Committee will determine the terms and conditions of such other
stock-based award, including the consideration to be paid for shares of Common
Stock or other securities delivered pursuant to a purchase right granted under
such award. The value of such consideration shall be the fair market value of
such shares or other securities as of the date such purchase right is granted.
Duration, Termination and Amendment. Unless earlier discontinued or
terminated by the Board of Directors, no awards may be granted under the 2001
Incentive Stock Plan ten years after the effective date of the 2001 Incentive
Stock Plan. The 2001 Incentive Stock Plan permits the Board of Directors to
amend, alter, suspend, discontinue or terminate the 2001 Incentive Stock Plan at
any time, except that prior stockholder approval will be required for any
amendment to the 2001 Incentive Stock Plan that requires stockholder approval
under the rules or regulations of the Nasdaq Stock Market or any securities
exchange that are applicable to Enzon.
31
Federal Tax Consequences
The following is a summary of the principal federal income tax consequences
generally applicable to awards under the 2001 Incentive Stock Plan.
Stock Options and Stock Appreciation Rights. The grant of an option or
stock appreciation right is not expected to result in any taxable income for the
recipient. The holder of an Incentive Stock Option generally will have no
taxable income upon exercising the Incentive Stock Option (except that a
liability may arise pursuant to the alternative minimum tax), and Enzon will not
be entitled to a tax deduction when an Incentive Stock Option is exercised. Upon
exercising a non-qualified stock option, the optionee must recognize ordinary
income equal to the excess of the fair market value of the shares of Common
Stock acquired on the date of exercise over the exercise price, and Enzon will
be entitled at that time to a tax deduction for the same amount. Upon exercising
a stock appreciation right, the amount of any cash received and the fair market
value on the exercise date of any shares of Common Stock received are taxable to
the recipient as ordinary income and deductible by Enzon. The tax consequence to
an optionee upon a disposition of shares acquired through the exercise of an
option will depend on how long the shares have been held and whether such shares
were acquired by exercising an Incentive Stock Option or by exercising a
non-qualified stock option or stock appreciation right. Generally, there will be
no tax consequence to Enzon in connection with disposition of shares acquired
under an option, except that Enzon may be entitled to a tax deduction in the
case of a disposition of shares acquired under an Incentive Stock Option before
the applicable Incentive Stock Option holding periods set forth in the Internal
Revenue Code have been satisfied.
Other Awards. With respect to other awards granted under the 2001 Incentive
Stock Plan that are payable either in cash or shares of Common Stock that are
either transferable or not subject to substantial risk of forfeiture, the holder
of such an award will recognize ordinary income at the time of receipt of such
award, in an amount equal to the excess of (a) the cash or the fair market value
of the shares of Common Stock received (determined as of the date of such
receipt) over (b) the amount (if any) paid for such shares of Common Stock by
the holder of the award, and Enzon will be entitled at that time to a deduction
for the same amount. With respect to an award that is payable in shares of
Common Stock that are restricted as to transferability and subject to
substantial risk of forfeiture, unless a special election is made pursuant to
the Internal Revenue Code, the holder of the award must recognize ordinary
income at the time the restrictions lapse equal to the excess of (i) the fair
market value of the shares of Common Stock received (determined as of the first
time the shares become transferable or not subject to substantial risk of
forfeiture, whichever occurs earlier) over (ii) the amount (if any) paid for
such shares of Common Stock by the holder, and Enzon will be entitled at that
time to a tax deduction for the same amount.
Satisfaction of Tax Obligations. Under the 2001 Incentive Stock Plan, the
Compensation Committee may permit participants receiving or exercising awards,
subject to the discretion of the Compensation Committee and upon such terms and
conditions as it may impose, to surrender shares of Common Stock (either shares
received upon the receipt or exercise of the award or shares previously owned by
the participant) to Enzon to satisfy federal and state tax obligations. In
addition, pursuant to its general authority outside of the 2001 Incentive Stock
Plan, the Compensation Committee may grant, subject to its discretion, a cash
bonus to a participant in order to provide funds to pay all or a portion of
federal and state taxes due as a result of the exercise or receipt of (or lapse
of restrictions relating to) an award. The amount of any such bonus will be
taxable to the participant as ordinary income, and Enzon will have a
corresponding deduction equal to such amount (subject to the usual rules
concerning reasonable compensation).
Section 162(m) Requirements. The 2001 Incentive Stock Plan has been
designed to meet the requirements of Section 162(m) of the Internal Revenue Code
regarding the deductibility of executive compensation and the Company strives to
maximize the deductibility of tax consequences where reasonable. However, there
are occasions when it is not feasible to take all steps which are necessary, and
in this instance non-deductibility could occur in certain instances.
32
The following table sets forth information regarding outstanding options
and shares reserved for future issuance under our equity compensation plans as
of December 31, 2005 (in thousands, except per share data):
Remaining
Plan Category To be issued Exercise price available
- ---------------------------------------------- -------------- ----------------- ---------------
(a) (b) (c)
Equity compensation plans approved by security holders 6,114 $14.17 2,318
Equity compensation plans not approved by security holders - - -
------------- ----------------- ---------------
Total 6,114 $14.17 2,318
============= ================= ===============
(a) Number of securities to be issued upon exercise of outstanding options.
(b) Weighted-average exercise price of outstanding options.
(c) Number of securities remaining available for future issuance under equity
compensation plans of which 817,000 were reserved for issuance upon vesting
of outstanding restricted stock unit awards.
As of April 14, 2006, ___________ shares had been issued upon exercise of
options granted under the Plan, options to purchase __________ shares were
outstanding and __________ shares remained available for future grant. The
following table sets forth information with respect to the stock options and
restricted stock granted to the Named Executive Officers, all current executive
officers as a group, all current and former non-employee directors as a group,
and all employees and consultants (including all current officers who are not
executive officers):
Number of Shares of
Restricted Stock and
Shares Underlying Weighted
Options Granted Under Average
the 2001 Incentive Exercise Price
Name Stock Plan per Share
- ------------------------------------------------------------------------- --------------------- ---------------
Jeffrey H. Buchalter 1,263,234 $11.42
Paul S. Davit 167,500 10.69
Ralph del Campo 267,500 13.57
Dr. Ivan D. Horak 92,500 7.06
Craig A. Tooman 225,000 11.04
Executive Officers as a Group (5 persons) 2,015,734 11.40
Non-Employee Directors as a Group (12 persons) 1,212,462 19.27
All Employees Other than Executive Officers as a Group (347 persons) 3,421,000 14.16
--------------------- ---------------
Total 6,649,196 $14.26
The Board of Directors recommends a vote FOR the amendment to the 2001
Incentive Stock Plan as proposed (Proposal No. 2 on the proxy card). The
affirmative vote of a majority of the shares represented in person or by proxy
at the meeting and entitled to vote on the proposal will be required for
approval.
33
PROPOSAL NO. 3 - AMENDMENT AND RESTATEMENT OF THE COMPANY'S RESTATED
CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF
COMMON STOCK
Our current Restated Certificate of Incorporation authorizes the issuance
of 90,000,000 shares of common stock and 3,000,000 shares of preferred stock.
The Board has proposed an amendment and restatement of the Restated Certificate
of Incorporation in the form attached as Appendix C to increase the number of
authorized shares of common stock from 90,000,000 to 170,000,000. The Restated
Certificate of Incorporation will remain the same in all other respects. The
stockholders are being asked to approve the proposed amendment in accordance
with Delaware law.
As of March 31, 2006, there were approximately 43,786,786 shares of common
stock issued and outstanding. This number does not include 8,432,000 shares
reserved for issuance as of March 31, 2006 pursuant to outstanding options to
purchase shares of Common Stock and outstanding restricted stock units, as well
as 5,551,085 shares reserved for issuance as of March 31, 2006 upon conversion
of our 4 1/2% Convertible Subordinated Notes due 2008.
The following is the text of Article THIRD Section 4(A) of the Restated
Certificate of Incorporation, as proposed to be amended:
"(A) The total number of shares of capital stock which the Corporation
shall have authority to issue is 173,000,000 shares, of which 170,000,000 shares
shall be Common Stock, par value $0.01 per share, and 3,000,000 shares shall be
Preferred Stock, par value $0.01 per share."
The purpose of the proposed amendment is to allow us to have a sufficient
number of shares of authorized and unissued common stock which can be issued in
connection with such corporate purposes as may be considered advisable by the
Board. Having such shares available for issuance in the future will give us
greater flexibility and will allow such shares to be issued as determined by the
Board without the expense and delay of a special stockholders' meeting. Such
stock could be used, for example, for acquisitions, for stock splits or stock
dividends, for our employee benefit plans, or in connection with equity
financings.
The increase in authorized common stock will not have any immediate effect
on the rights of existing stockholders. However, the Board will have the
authority to issue authorized common stock without requiring future stockholder
approval of such issuances, except as may be required by the Certificate of
Incorporation and applicable law and regulations. To the extent that the
additional authorized shares are issued in the future, they will decrease the
existing stockholders' percentage equity ownership and, depending upon the price
at which they are issued as compared to the price paid by existing stockholders
for their shares, could be dilutive to our existing stockholders. The holders of
common stock have no preemptive rights to subscribe for or purchase any
additional shares of common stock that may be issued in the future.
The increase in the authorized number of shares of common stock and the
subsequent issuance of such shares could have the effect of delaying or
preventing a change in control of the Company without further action by the
stockholders. Shares of authorized and unissued common stock could (within the
limits imposed by applicable law) be issued in one or more transactions which
would make a change in control of the Company more difficult, and therefore less
likely. Any such issuance of additional stock could have the effect of diluting
the earnings per share and book value per share of outstanding shares of common
stock, and such additional shares could be used to dilute the stock ownership or
voting rights of a person seeking to obtain control of the Company. The Board is
not aware of any attempt to take control of the Company and has not presented
this proposal with the intention that the increase in the authorized shares of
common stock be used as a type of antitakeover device.
The Board of Directors recommends a vote FOR the amendment and restatement
of the Restated Certificate of Incorporation as proposed (Proposal No. 3 on the
proxy card). The affirmative vote of a majority of the outstanding shares of
common stock of the Company entitled to vote at the meeting will be required for
approval of Proposal No. 3.
34
PROPOSAL NO. 4 - RATIFICATION OF AUDITORS
The Finance and Audit Committee of the Board of Directors, pursuant to
authority granted by the Board of Directors, has approved the retention of KPMG
LLP ("KPMG"), independent registered public accounting firm, to audit the
consolidated financial statements of the Company for the fiscal year ending
December 31, 2006. KPMG served as auditor of the consolidated financial
statements of the Company for the fiscal years ended June 30, 2005, 2004, and
2003 and the six-month transition period ended December 31, 2005.
Representatives of KPMG are expected to be present at the Annual Meeting and
will have the opportunity to make a statement should they desire to do so. Such
representatives are also expected to be available to respond to questions.
Pre-Approval Policies and Procedures.
The Audit Committee is required to pre-approve the audit and non-audit
services performed by the independent accountants in order to assure that the
provision of such services does not impair the accountants' independence. The
Audit Committee specifically pre-approves all audit fees, audit related fees,
tax service fees and all other fees. The Audit Committee has delegated authority
to the Chair of the Committee to approve any services not specifically
pre-approved by the Committee provided that disclosure of such services and fees
is made to the Audit Committee at the next scheduled meeting following such
approval.
Audit Fees
The following table sets forth the aggregate fees billed to the Company by
KPMG for professional services rendered for the six-month transition period
ended December 31, 2005 and for the fiscal years ending June 30, 2005 and 2004:
Year Ended June 30,
Six-Month ----------------------------------------
Transition Period Ended 2005 2004
December 31, 2005
------------------------------ ----------------- ------------------
Audit fees (1) $926,000 $1,018,000 $210,000
Audit related fees (2) - 53,000 10,000
Tax fees (3) - 93,000
------------------------------ ----------------- ------------------
Total fees $926,000 $1,071,000 $313,000
============================== ================= ==================
(1) Includes services relating to the audit of the annual consolidated
financial statements, review of quarterly financial statements,
issuance of consents, review of documents filed with the SEC,
accounting consultations, and the audit of management effectiveness of
internal controls over financial reporting.
(2) Includes services relating to the audit of employee benefit plans.
(3) Includes services for tax compliance and tax advisory services.
The Finance and Audit Committee has considered whether the provision of all
other services by KPMG is compatible with maintaining KPMG's independence and
concluded that KPMG is "independent".
The Board of Directors recommends a vote FOR ratification of the selection
of KPMG, independent registered public accountants, to audit the consolidated
financial statements of the Company for the fiscal year ending December 31, 2006
(Proposal No. 4 on the Proxy Card).
ANNUAL REPORT TO STOCKHOLDERS
The Company's Annual Report to Stockholders, including its Transition
Report on Form 10-K for the six-month transition period ended December 31, 2005,
accompanies this Proxy Statement.
35
STOCKHOLDERS' PROPOSALS
In order for a stockholder to have a proposal included in the proxy
statement for the 2007 annual stockholders' meeting, the proposal must comply
with both the procedures identified by Rule 14a-8 under the Securities Exchange
Act of 1934, as amended (the Exchange Act") and be received in writing by the
Company's Secretary on or before 5:00 P.M. Eastern Standard Time on December 19,
2006. Such a proposal will be considered at the 2007 annual stockholders'
meeting.
Article II Section 2.15 of the Company's By-laws requires a stockholder's
proposal to be delivered to or mailed and received by the Secretary of the
Company not later than 120 days prior to the 2007 annual stockholders' meeting
in order for a stockholder's proposal to be considered at such meeting. We
expect that the 2007 annual stockholders meeting will be held on May 17, 2007,
so any such proposal must be received by January 17, 2007. The Company's Bylaws
further require the stockholder to provide to the Secretary of the Company,
among other things, the name and address of the stockholder who intends to make
the nominations or propose the business, the name and address of the person or
persons to be nominated, a description of the business to be proposed and a
representation that the stockholder is a holder of record of stock of the
Company entitled to vote at such meeting. The chairman of the meeting may refuse
to acknowledge the nomination of any person or the proposal of any business not
made in compliance with the foregoing procedure. Rule 14a-8 under the Exchange
Act requires the stockholder to comply with the provisions of that rule in order
for the stockholder's proposal to be included in the Company's proxy statement.
In order for a stockholder's proposal to be included in the Company's proxy
statement for the 2007 annual meeting, Rule 14a-8 requires that such proposal be
received at the Company's principal executive offices not less than 120 calendar
days before the date of this proxy statement (or December 19, 2006).
Any proposal received after January 17, 2007 will be considered untimely
within Rule 14a-4(c) under the Exchange Act and the persons named in the proxy
for such meeting may exercise their discretionary voting power with respect to
such proposal, including voting against such proposal, even though it is not
discussed in the proxy statement for such meeting.
GENERAL
The cost of soliciting proxies will be borne by the Company. In addition to
mailing, proxies may be solicited by personal interview and telephone and by
directors, officers and regular employees of the Company, without special
compensation therefor. The Company expects to reimburse banks, brokers and other
persons for their reasonable out-of-pocket expenses in handling proxy materials
for beneficial owners of the Company's Common Stock.
Unless contrary instructions are indicated on the proxy card, all shares of
Common Stock represented by valid proxies received pursuant to this solicitation
(and not revoked before they are voted) will be voted FOR the election of the
nominees for directors named herein and FOR Proposals No. 2, No. 3 and No. 4.
Any proxy given pursuant to this solicitation may be revoked by the person
giving it at any time before it is voted. Proxies may be revoked by filing with
the Secretary of the Company written notice of revocation bearing a later date
than the proxy, by duly executing a subsequent proxy relating to the same shares
of Common Stock or by attending the Annual Meeting and voting in person.
Attendance at the Annual Meeting will not in and of itself constitute revocation
of a proxy unless the stockholder votes his or her shares of Common Stock in
person at the Annual Meeting. Any notice revoking a proxy should be sent to the
Secretary of the Company, Paul S. Davit, at Enzon Pharmaceuticals, Inc., 685
Route 202/206, Bridgewater, New Jersey 08807.
The Board of Directors knows of no business other than that set forth above
to be transacted at the meeting, but if other matters requiring a vote of the
stockholders arise, the persons designated as proxies will vote the shares of
Common Stock represented by the proxies in accordance with their judgment on
such matters. If a stockholder specifies a different choice on the proxy, his or
her shares of Common Stock will be voted in accordance with the specification so
made.
Please complete, sign and date the enclosed proxy card, which is revocable
as described herein, and mail it promptly in the enclosed postage-paid envelope.
36
IT IS IMPORTANT THAT PROXIES BE RETURNED PROMPTLY. WE URGE YOU TO FILL IN,
SIGN AND RETURN THE ACCOMPANYING PROXY CARD, NO MATTER HOW LARGE OR SMALL YOUR
HOLDINGS MAY BE.
By order of the Board of Directors,
/s/ Paul S. Davit
Paul S. Davit
Corporate Secretary
Bridgewater, New Jersey
April __, 2006
37
APPENDIX A
ENZON PHARMACEUTICALS, INC.
FINANCE AND AUDIT COMMITTEE CHARTER
Purpose
The Finance and Audit Committee (the "Committee") of the Board of Directors (the
"Board") of Enzon Pharmaceuticals, Inc. (the "Company"), is appointed to assist
the Board in its oversight responsibilities by monitoring:
1. the integrity of the Company's financial reporting process and
financial statements;
2. the systems of internal controls and controls over financial
reporting,
3. the compliance by the Company with legal and regulatory requirements,
and;
4. the performance and independence of the Company's independent
auditors.
Membership
The Committee shall be comprised of not less than three members of the Board,
shall be appointed by the Board for such terms as the Board may determine and
shall meet the requirements of applicable Securities and Exchange Commission
(the "SEC") and NASD regulations and rules. The Board will designate a Chair of
the Committee. Members of the Committee shall be directors who:
1. Meet the applicable SEC and NASD independence and experience
requirements,
2. Shall have the ability to read and understand the Company's basic
financial statements or shall at the time of appointment undertake
training for that purpose. and;
3. At least one member shall be designated by the Board as being a
"financial expert" through having demonstrated accounting or related
financial management expertise.
Charter
The Committee shall maintain a written charter that is approved by the Board.
The charter will be reviewed and updated at least annually. The Committee will
report its activities to the full Board on a regular basis including an annual
assessment of Committee performance.
Meetings
The Committee will meet at least four times per year, or more frequently as
circumstances dictate. The Committee shall meet regularly with the Chief
Financial Officer, the independent auditors and the head of internal auditing
(if applicable) in private executive sessions.
Responsibilities
The function of the Committee is oversight.
Management of the Company is responsible for the preparation, presentation and
integrity of the Company's financial statements and for the maintenance of
policies and internal controls necessary to assure compliance with accounting
standards and applicable laws and regulations.
The independent auditors are responsible for planning and conducting an audit of
the Company's consolidated financial statements, reviews of the Company's
quarterly financial statements and performing such other procedures required by
applicable Statements of Auditing Standards or requested by the Committee.
The Committee shall have the following duties and responsibilities:
Oversight of the Independent Auditors:
1. The Committee is directly responsible for the appointment,
compensation and oversight of the work of the independent auditors,
who shall report directly to the Committee.
2. Pre-approve, or adopt appropriate procedures to pre-approve, all audit
and non-audit services to be provided by the independent auditors.
3. Review the audit scope and audit plan,
4. Obtain and review, at least annually, a report which describes the
independent auditors' internal compliance procedures, any issues
related to peer review or other quality reviews of the auditors' firm
and the independence of the auditors.
5. Obtain and review, at least annually, a formal written statement from
the independent auditor regarding all relationships that may exist
between the independent auditor and the Company consistent with the
Independence Standards Board, Statement No. 1, regarding relationships
and services, which may impact the objectivity and independence of the
independent auditor.
6. The independent auditors shall inform the Committee of reasons for and
the disposition of consultations with their national office regarding
the Company.
7. Set hiring policies for employees or former employees of the
independent auditors.
8. Resolve disagreements between management and the independent auditors.
Oversight of the Company's Internal Controls:
9. Discuss the adequacy of the company's internal controls with
management and the independent auditors including reports regarding
significant deficiencies and material weaknesses in the design or
operation of internal controls. Review steps taken by management to
remediate significant deficiencies or material weaknesses.
10. Review and discuss with management and the independent auditors,
management's annual report on the Company's internal control system
and the independent auditors attestation regarding management's
report.
11. Review the Chief Executive Officer's and Chief Financial Officer's
certifications filed in SEC forms 10K and 10Q.
12. Review and approve related party transactions disclosed in SEC forms
10K and 10Q.
Oversight of the Financial Statements
13. Review with management and the independent auditors prior to the
filing of Forms 10-K and 10-Q, the annual and quarterly financial
statements of the Company, including: (i) any material changes in
accounting principles or practices used in preparing the financial
statements (ii) disclosures relating to internal controls over
financial reporting; (iii) items required by Statement of Auditing
Standards 61 as in effect at that time in the case of the annual
statements and Statement of Auditing Standards 100 as in effect at
that time in the case of the quarterly statements; and (iv) meet to
review the Company's specific disclosures under "Management's
Discussion and Analysis of Financial Conditions and Results of
Operations" included in the Forms 10-K or 10-Q.
14. Recommend to the Board, approval of the financial statements to be
included in the annual report on Form 10-K.
15. Review earnings press releases, as well as Company policies with
respect to earnings press releases, financial information and earnings
guidance provided to analysts and rating agencies.
16. Review the role and operation of the Disclosure Committee and meeting
minutes.
Oversight of Compliance with Legal and Regulatory Requirements
17. Discuss and review with management, company counsel, and the
independent auditors any significant issues raised by counsel
concerning litigation, contingencies or claims, and any material
reports or inquiries received from regulators or governmental
agencies. The Committee should understand how such matters are
reflected in the Company's financial statements.
18. Obtain, review and evaluate reports from management with respect to
the Company's policies and procedures regarding compliance with
applicable legal and regulatory requirements, and the Company's Code
of Conduct and Corporate Values.
2
Other Authority
19. Review procedures to promote and protect employee reporting of
suspected fraud or wrongdoing relating to accounting, auditing and
financial reporting including procedures for: (i) receiving, retaining
and addressing complaints received relating to such matters; (ii)
enabling employees to submit to the Committee, on a confidential and
anonymous basis, any concerns regarding such matters, and; (iii)
protecting reporting employees from retaliation.
20. Provide the report of the Committee as required by the SEC in the
Company's annual proxy statement.
21. Inquire of management as to significant financial risks or exposures
and evaluate steps taken to assess, minimize and manage such risks.
22. Provide input to the CEO on performance of the Chief Financial Officer
and finance department and to the Compensation Committee of the Board
on performance of the Chief Financial Officer.
23. Conduct or authorize investigations into any matters within the
Committee's scope of responsibilities. The Committee may retain (at
the Company's expense) independent counsel, accountants, or others to
assist in the conduct of any investigation.
Internal Audit
If an Internal Audit function is formed, the Committee will review the
scope and staffing of the functions. The head of the Internal Audit department
will report directly to the Committee and will review plans and findings of
internal audits and will meet in executive session with the Committee.
3
APPENDIX B
Enzon Pharmaceuticals, Inc.
2001 INCENTIVE STOCK PLAN AS AMENDED*
* As proposed to be amended
Section 1. Purpose
The purpose of the Plan is to promote the interests of the Company and its
shareholders by aiding the Company in attracting and retaining employees,
officers, consultants, independent contractors and Non-Employee Directors
capable of contributing to the future success of the Company, to offer such
persons incentives to put forth maximum efforts for the success of the Company's
business and to afford such persons an opportunity to acquire a proprietary
interest in the Company.
Section 2. Definitions
As used in the Plan, the following terms shall have the meanings set forth
below:
1 "Affiliate" shall mean (i) any entity that, directly or indirectly through
one or more intermediaries, is controlled by the Company and (ii) any
entity in which the Company has a significant equity interest, in each case
as determined by the Committee.
2 "Award" shall mean any Option, Stock Appreciation Right, Restricted Stock,
Restricted Stock Unit, Performance Award, Dividend Equivalent, Other Stock
Grant or Other Stock-Based Award granted under the Plan.
3 "Award Agreement" shall mean any written agreement, contract or other
instrument or document evidencing any Award granted under the Plan. Each
Award Agreement shall be subject to the applicable terms and conditions of
the Plan and any other terms and conditions (not inconsistent with the
Plan) determined by the Committee.
4 "Board" shall mean the Board of Directors of the Company.
5 "Code" shall mean the Internal Revenue Code of 1986, as amended from time
to time, and any regulations promulgated thereunder.
6 "Committee" shall mean a committee of Directors designated by the Board to
administer the Plan. The Committee shall be comprised of not less than such
number of Directors as shall be required to permit Awards granted under the
Plan by the Committee to qualify under Rule 16b-3, and each member of the
Committee shall be a "Non-Employee Director" within the meaning of Rule
16b-3 and an "outside director" within the meaning of Section 162(m) of the
Code. The Company expects to have the Plan administered in accordance with
the requirements for the award of "qualified performance-based
compensation" within the meaning of Section 162(m) of the Code.
7 "Company" shall mean Enzon Pharmaceuticals, Inc., a Delaware corporation,
and any successor corporation.
8 "Director" shall mean a member of the Board, including Non-Employee
Directors.
9 "Dividend Equivalent" shall mean any right granted under Section 6(E) of
the Plan.
10 "Eligible Person" shall mean any employee, officer, consultant, independent
contractor or Director (including any Non-Employee Director) providing
services to the Company or any Affiliate whom the Committee determines to
be an Eligible Person.
11 "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended.
12 "Fair Market Value" shall mean, with respect to any property (including,
without limitation, any Shares or other securities), the fair market value
of such property determined by such methods or procedures as shall be
established from time to time by the Committee. Notwithstanding the
foregoing, unless otherwise determined by the Committee, the Fair Market
Value of a Share as of a given date shall be, if the Shares are then traded
on the Nasdaq National Market, the last reported sale price of one Share as
reported on the Nasdaq National Market on such date or, if the Nasdaq
National Market is not open for trading on such date, on the most recent
preceding date when it is open for trading.
13 "Family Members" shall be those persons related to a Participant as
determined by the Committee.
14 "Incentive Stock Option" shall mean an option granted under Section 6A of
the Plan that is intended to meet the requirements of Section 422 of the
Code or any successor provision.
15 "Non-Employee Director" shall have the meaning ascribed in Rule 16b-3
promulgated under the Exchange Act or any successor provision.
16 "Non-Qualified Stock Option" shall mean an option granted under Section 6A
of the Plan that is not intended to be an Incentive Stock Option.
17 "Option" shall mean an Incentive Stock Option or a Non-Qualified Stock
Option.
18 "Other Stock Grant" shall mean any right granted under Section 6F of the
Plan.
19 "Other Stock-Based Award" shall mean any right granted under Section 6G of
the Plan.
20 "Participant" shall mean an Eligible Person designated to be granted an
Award under the Plan.
21 "Performance Award" shall mean any right granted under Section 6D of the
Plan.
22 "Person" shall mean any individual, corporation, partnership, association
or trust.
23 "Plan" shall mean the Enzon Pharmaceuticals, Inc. 2001 Incentive Stock
Plan, as amended from time to time, the provisions of which are set forth
herein.
24 "Plan Year" shall mean a consecutive 12-month period ending on December 31
of each year.
25 "Reload Option" shall mean any Option granted under Section 6A(5) of the
Plan.
26 "Restricted Stock" shall mean any Shares granted under Section 6C of the
Plan.
27 "Restricted Stock Unit" shall mean any unit granted under Section 6C of the
Plan evidencing the right to receive a Share (or a cash payment equal to
the Fair Market Value of a Share) at some future date.
28 "Rule 16b-3" shall mean Rule 16b-3 promulgated by the Securities and
Exchange Commission under the Exchange Act, or any successor rule or
regulation.
2
29 "Share" or "Shares" shall mean shares of common stock, $0.01 par value per
share, of the Company or such other securities or property as may become
subject to Awards pursuant to an adjustment made under Section 4C of the
Plan.
30 "Stock Appreciation Right" shall mean any right granted under Section 6B of
the Plan.
Section 3. Administration
A. Power and Authority of the Committee. The Plan shall be administered by
the Committee. Subject to the express provisions of the Plan and to applicable
law, the Committee shall have full power and authority to: (i) designate
Participants; (ii) determine the type or types of Awards to be granted to each
Participant under the Plan; (iii) determine the number of Shares to be covered
by (or the method by which payments, or other rights are to be calculated in
connection with) each Award; (iv) determine the terms and conditions of any
Award or Award Agreement; (v) amend the terms and conditions of any Award or
Award Agreement and accelerate the exercisability of any Award or the lapse of
restrictions relating to any Award; (vi) determine whether, to what extent and
under what circumstances Awards may be exercised in cash, Shares, promissory
notes, other securities, other Awards or other property, or canceled, forfeited
or suspended; (vii) determine whether, to what extent and under what
circumstances cash, Shares, promissory notes, other securities, other Awards,
other property and other amounts payable with respect to an Award under the Plan
shall be deferred either automatically or at the election of the holder thereof
or the Committee; (viii) interpret and administer the Plan and any instrument or
agreement, including an Award Agreement, relating to the Plan; (ix) establish,
amend, suspend or waive such rules and regulations and appoint such agents as it
shall deem appropriate for the proper administration of the Plan; and (x) make
any other determination and take any other action that the Committee deems
necessary or desirable for the administration of the Plan. Unless otherwise
expressly provided in the Plan, all designations, determinations,
interpretations and other decisions under or with respect to the Plan or any
Award shall be within the sole discretion of the Committee, may be made at any
time and shall be final, conclusive and binding upon any Participant, any holder
or beneficiary of any Award and any employee of the Company or any Affiliate.
B. Delegation. The Committee may delegate its powers and duties under the
Plan to one or more Directors or officers of the Company, or to a committee of
Directors or officers, subject to such terms, conditions and limitations as the
Committee may establish in its sole discretion, provided, however, that the
Committee shall not delegate its powers and duties under the Plan (i) with
regard to officers or directors of the Company or any Affiliate who are subject
to Section 16 of the Exchange Act or (ii) in such a manner as would cause the
Plan not to comply with the requirements of Section 162(m) of the Code.
C. Power and Authority of the Board. Notwithstanding anything to the
contrary contained herein, the Board may, at any time and from time to time,
without any further action of the Committee, exercise the powers and duties of
the Committee under the Plan.
Section 4. Shares Available for Awards
A. Shares Available. Subject to adjustment as provided in Section 4C of the
Plan, the aggregate number of Shares that may be issued under all Awards under
the Plan shall be 10,000,000; provided that, any Shares with respect to which
Awards may be issued, but are not issued, under the Plan in any Plan Year shall
be carried forward and shall be available to be covered by Awards issued in any
subsequent Plan Year in which Awards may be issued under the Plan. Shares to be
issued under the Plan may be either authorized but unissued Shares or Shares
acquired in the open market or otherwise. Any Shares that are used by a
Participant as full or partial payment to the Company of the purchase price
relating to an Award, or in connection with the satisfaction of tax obligations
relating to an Award, shall again be available for granting Awards (other than
Incentive Stock Options) under the Plan. In addition, if any Shares covered by
an Award or to which an Award relates are not purchased or are forfeited, or if
an Award otherwise terminates without delivery of any Shares, then the number of
3
Shares counted against the aggregate number of Shares available under the Plan
with respect to such Award, to the extent of any such forfeiture or termination,
shall again be available for granting Awards under the Plan. Notwithstanding the
foregoing, the number of Shares available for granting Incentive Stock Options
under the Plan shall not exceed 10,000,000 shares subject to adjustment as
provided in the Plan and subject to the provisions of Section 422 or 424 of the
Code or any successor provision.
B. Accounting for Awards. For purposes of this Section 4, if an Award
entitles the holder thereof to receive or purchase Shares, the number of Shares
covered by such Award or to which such Award relates shall be counted on the
date of grant of such Award against the aggregate number of Shares available for
granting Awards under the Plan.
C. Adjustments. In the event that the Committee shall determine that any
dividend or other distribution (whether in the form of cash, Shares, other
securities or other property), recapitalization, stock split, reverse stock
split, reorganization, merger, consolidation, split-up, spin-off, combination,
issuance of warrants or other rights to purchase Shares or other securities of
the Company to all holders of common stock pro rata whether as a dividend or
otherwise or other similar corporate transaction or event affects the Shares
such that an adjustment is determined by the Committee to be appropriate in
order to prevent dilution or enlargement of the benefits or potential benefits
intended to be made available under the Plan, then the Committee shall, in such
manner as it may deem equitable, adjust any or all of (i) the number and type of
Shares (or other securities or other property) that thereafter may be made the
subject of Awards, (ii) the number and type of Shares (or other securities or
other property) subject to outstanding Awards and (iii) the purchase or exercise
price with respect to any Award; provided, however, that the number of Shares
covered by any Award or to which such Award relates shall always be a whole
number.
D. Award Limitations Under the Plan. No Eligible Person may be granted any
Award or Awards under the Plan, the value of which Award or Awards is based
solely on an increase in the value of the Shares after the date of grant of such
Award or Awards, for more than 1,000,000 Shares (subject to adjustment as
provided for in Section 4(c) of the Plan), in the aggregate in any calendar
year. The foregoing annual limitation specifically includes the grant of any
Award or Awards representing "qualified performance-based compensation" within
the meaning of Section 162(m) of the Code.
Section 5. Eligibility.
Any Eligible Person shall be eligible to be designated a Participant. In
determining which Eligible Persons shall receive an Award and the terms of any
Award, the Committee may take into account the nature of the services rendered
by the respective Eligible Persons, their present and potential contributions to
the success of the Company or such other factors as the Committee, in its
discretion, shall deem relevant. Notwithstanding the foregoing, an Incentive
Stock Option may only be granted to full or part-time employees (which term as
used herein includes, without limitation, officers and Directors who are also
employees), and an Incentive Stock Option shall not be granted to an employee of
an Affiliate unless such Affiliate is also a "subsidiary corporation" of the
Company within the meaning of Section 424(f) of the Code or any successor
provision.
4
Section 6.
Awards
A. Options. The Committee is hereby authorized to grant Options to Eligible
Persons with the following terms and conditions and with such additional
terms and conditions not inconsistent with the provisions of the Plan as
the Committee shall determine:
1. Exercise Price. The purchase price per Share purchasable under an
Option shall be determined by the Committee; provided, however, that
such purchase price shall not be less than 100% of the Fair Market
Value of a Share on the date of grant of such Option.
2. Option Term. The term of each Option shall be fixed by the Committee,
but, shall in no event exceed 10 years from the date on which such
Option is granted.
3. Time and Method of Exercise. The Committee shall determine the time or
times at which an Option may be exercised in whole or in part and the
method or methods by which, and the form or forms (including, without
limitation, cash, Shares, promissory notes, other securities, other
Awards or other property, or any combination thereof, having a Fair
Market Value on the exercise date equal to the applicable exercise
price) in which, payment of the exercise price with respect thereto
may be made or deemed to have been made.
4. Incentive Stock Options. Notwithstanding anything in the Plan to the
contrary, the following additional provisions shall apply to the grant
of stock options which are intended to qualify as Incentive Stock
Options:
(a) The aggregate Fair Market Value (determined as of the time the
option is granted) of the Shares with respect to which Incentive
Stock Options are exercisable for the first time by any
Participant during any calendar year (under this Plan and all
other plans of the Company and its Affiliates) shall not exceed
$100,000.
(b) All Incentive Stock Options must be granted within ten years from
the earlier of the date on which this Plan was adopted by the
Board or the date this Plan was approved by the shareholders of
the Company.
(c) Unless sooner exercised, all Incentive Stock Options shall expire
and no longer be exercisable no later than 10 years after the
date of grant; provided, however, that in the case of a grant of
an Incentive Stock Option to a Participant who, at the time such
Option is granted, owns (within the meaning of Section 422 of the
Code) stock possessing more than 10% of the total combined voting
power of all classes of stock of the Company or of its Affiliate,
such Incentive Stock Option shall expire and no longer be
exercisable no later than 5 years from the date of grant.
(d) The purchase price per Share for an Incentive Stock Option shall
be not less than 100% of the Fair Market Value of a Share on the
date of grant of the Incentive Stock Option; provided, however,
that, in the case of the grant of an Incentive Stock Option to a
Participant who, at the time such Option is granted, owns (within
the meaning of Section 422 of the Code) stock possessing more
than 10% of the total combined voting power of all classes of
stock of the Company or of its Affiliate, the purchase price per
Share purchasable under an Incentive Stock Option shall be not
less than 110% of the Fair Market Value of a Share on the date of
grant of the Inventive Stock Option.
(e) Any Incentive Stock Option authorized under the Plan shall
contain such other provisions as the Committee shall deem
advisable, but shall in all events be consistent with and contain
all provisions required in order to qualify the Option as an
Incentive Stock Option.
5
5. Reload Options. The Committee may grant Reload Options, separately
or together with another Option, pursuant to which, subject to the terms
and conditions established by the Committee, the Participant would be
granted a new Option when the payment of the exercise price of a previously
granted option is made by the delivery of Shares owned by the Participant
pursuant to Section 6A(3) hereof or the relevant provisions of another plan
of the Company, and/or when Shares are tendered or withheld as payment of
the amount to be withheld under applicable income tax laws in connection
with the exercise of an Option, which new Option would be an Option to
purchase the number of Shares not exceeding the sum of (A) the number of
Shares so provided as consideration upon the exercise of the previously
granted option to which such Reload Option relates and (B) the number of
Shares, if any, tendered or withheld as payment of the amount to be
withheld under applicable tax laws in connection with the exercise of the
option to which such Reload Option relates pursuant to the relevant
provisions of the plan or agreement relating to such option. Reload Options
may be granted with respect to Options previously granted under the Plan or
any other stock option plan of the Company or may be granted in connection
with any Option granted under the Plan or any other stock option plan of
the Company at the time of such grant. Such Reload Options shall have a per
share exercise price equal to the Fair Market Value of one Share as of the
date of grant of the new Option. Any Reload Option shall be subject to
availability of sufficient Shares for grant under the Plan. Shares
surrendered as part or all of the exercise price of the Option to which it
relates that have been owned by the optionee less than six months will not
be counted for purposes of determining the number of Shares that may be
purchased pursuant to a Reload Option.
B. Stock Appreciation Rights. The Committee is hereby authorized to grant
Stock Appreciation Rights to Eligible Persons subject to the terms of the Plan
and any applicable Award Agreement. A Stock Appreciation Right granted under the
Plan shall confer on the holder thereof a right to receive upon exercise thereof
the excess of (i) the Fair Market Value of one Share on the date of exercise
(or, if the Committee shall so determine, at any time during a specified period
before or after the date of exercise) over (ii) the grant price of the Stock
Appreciation Right as specified by the Committee, which price shall not be less
than 100% of the Fair Market Value of one Share on the date of grant of the
Stock Appreciation Right. Subject to the terms of the Plan and any applicable
Award Agreement, the grant price, term, methods of exercise, dates of exercise,
methods of settlement and any other terms and conditions of any Stock
Appreciation Right shall be as determined by the Committee. The Committee may
impose such conditions or restrictions on the exercise of any Stock Appreciation
Right as it may deem appropriate.
6
C. Restricted Stock and Restricted Stock Units. The Committee is hereby
authorized to grant Restricted Stock and Restricted Stock Units to Eligible
Persons with the following terms and conditions and with such additional terms
and conditions not inconsistent with the provisions of the Plan as the Committee
shall determine:
1. Restrictions. Shares of Restricted Stock and Restricted Stock Units
shall be subject to such restrictions as the Committee may impose
(including, without limitation, a waiver by the Participant of the
right to vote or to receive any dividend or other right or property
with respect thereto), which restrictions may lapse separately or in
combination at such time or times, in such installments or otherwise
as the Committee may deem appropriate.
2. Stock Certificates. Any Restricted Stock granted under the Plan shall
be registered in the name of the Participant and shall bear an
appropriate legend referring to the terms, conditions and restrictions
applicable to such Restricted Stock.
3. Forfeiture. Except as otherwise determined by the Committee, upon a
Participant's termination of employment (as determined under criteria
established by the Committee) during the applicable restriction
period, all Shares of Restricted Stock and Restricted Stock Units held
by the Participant at such time shall be forfeited and reacquired by
the Company; provided, however, that the Committee may, when it finds
that a waiver would be in the best interest of the Company, waive in
whole or in part any or all remaining restrictions with respect to
Shares of Restricted Stock or Restricted Stock Units.
4. Aggregate Limit. The maximum number of shares of Restricted Stock and
Restricted Stock Units that the Committee may grant under the Plan
shall not exceed 50% of the total number of shares issuable pursuant
to all Awards under the Plan.
D. Performance Awards. The Committee is hereby authorized to grant
Performance Awards to Eligible Persons subject to the terms of the Plan and any
applicable Award Agreement. A Performance Award granted under the Plan (i) may
be denominated or payable in cash, Shares (including, without limitation,
Restricted Stock and Restricted Stock Units), other securities, other Awards or
other property and (ii) shall confer on the holder thereof the right to receive
payments, in whole or in part, upon the achievement of such performance goals
during such performance periods as the Committee shall establish. Subject to the
terms of the Plan and any applicable Award Agreement, the performance goals to
be achieved during any performance period, the length of any performance period,
the amount of any Performance Award granted, the amount of any payment or
transfer to be made pursuant to any Performance Award and any other terms and
conditions of any Performance Award shall be determined by the Committee.
E. Dividend Equivalents. The Committee is hereby authorized to grant
Dividend Equivalents to Eligible Persons under which the Participant shall be
entitled to receive payments (in cash, Shares, other securities, other Awards or
other property as determined in the discretion of the Committee) equivalent to
the amount of cash dividends paid by the Company to holders of Shares with
respect to a number of Shares determined by the Committee. Subject to the terms
of the Plan and any applicable Award Agreement, such Dividend Equivalents may
have such terms and conditions as the Committee shall determine.
F. Other Stock Grants. The Committee is hereby authorized, subject to the
terms of the Plan and any applicable Award Agreements, to grant to Eligible
Persons Shares without restrictions thereon as are deemed by the Committee to be
consistent with the purpose of the Plan.
G. Other Stock-Based Awards. The Committee is hereby authorized to grant to
Eligible Persons, subject to the terms of the Plan and any applicable Award
Agreements, such other Awards that are denominated or payable in, valued in
whole or in part by reference to, or otherwise based on or related to, Shares
(including, without limitation, securities convertible into Shares), as are
deemed by the Committee to be consistent with the purpose of the Plan. Shares or
other securities delivered pursuant to a purchase right granted under this
Section 6(G) shall be purchased for such consideration, which may be paid by
such method or methods and in such form or forms (including, without limitation,
cash, Shares, promissory notes, other securities, other Awards or other property
or any combination thereof), as the Committee shall determine, the value of
which consideration, as established by the Committee, shall not be less than
100% of the Fair Market Value of such Shares or other securities as of the date
such purchase right is granted.
7
H. General
1. Consideration for Awards. Awards shall be granted for no cash
consideration or for any cash or other consideration as may be
determined by the Committee or required by applicable law.
2. Awards May Be Granted Separately or Together. Awards may, in the
discretion of the Committee, be granted either alone or in addition
to, in tandem with or in substitution, for any other Award or any
award granted under any plan of the Company or any Affiliate other
than the Plan. Awards granted in addition to or in tandem with other
Awards or in addition to or in tandem with awards granted under any
such other plan of the Company or any Affiliate may be granted either
at the same time as or at a different time from the grant of such
other Awards or awards.
3. Forms of Payment under Awards. Subject to the terms of the Plan and of
any applicable Award Agreement, payments or transfers to be made by
the Company or an Affiliate upon the grant, exercise or payment of an
Award may be made in such form or forms as the Committee shall
determine (including, without limitation, cash, Shares, promissory
notes, other securities, other Awards or other property or any
combination thereof), and may be made in a single payment or transfer,
in installments or on a deferred basis, in each case in accordance
with rules and procedures established by the Committee. Such rules and
procedures may include, without limitation, provisions for the payment
or crediting of reasonable interest on installment or deferred
payments or the grant or crediting of Dividend Equivalents with
respect to installment or deferred payments.
8
4. Limits on Transfer of Awards. No Award (other than Other Stock Grants)
and no right under any such Award shall be transferable by a
Participant otherwise than by will or by the laws of descent and
distribution and the Company shall not be required to recognize any
attempted assignment of such rights by any Participant; provided,
however, that, if so determined by the Committee, a Participant may,
in the manner established by the Committee, (a) designate a
beneficiary or beneficiaries to exercise the rights of the Participant
and receive any property distributable with respect to any Award upon
the death of the Participant and (b) transfer Awards, except in the
case of an Incentive Stock Option, to Family Members pursuant to terms
determined by the Committee. Except as otherwise provided in this Plan
or in any applicable Award Agreement or amendment thereto (other than
an Award Agreement relating to an Incentive Stock Option), pursuant to
terms determined by the Committee, each Award or right under any Award
shall be exercisable during the Participant's lifetime only by the
Participant or, if permissible under applicable law, by the
Participant's guardian or legal representative. Except as otherwise
provided in this Plan or in any applicable Award Agreement or
amendment thereto (other than an Award Agreement relating to an
Incentive Stock Option), no Award or right under any such Award may be
pledged, alienated, attached or otherwise encumbered, and any
purported pledge, alienation, attachment or encumbrance thereof shall
be void and unenforceable against the Company or any Affiliate.
5. Term of Awards. The term of each Award shall be for such period as may
be determined by the Committee; provided, however, that in the case of
an Incentive Stock Option such Option shall not be exercisable after
the expiration of 10 years from the date such Option is granted.
6. Restrictions; Securities Exchange Listing. All Shares or other
securities delivered under the Plan pursuant to any Award or the
exercise thereof shall be subject to such restrictions as the
Committee may deem advisable under the Plan, applicable federal or
state securities laws and regulatory requirements, and the Committee
may cause appropriate entries to be made or legends to be placed on
the certificates for such Shares or other securities to reflect such
restrictions. If the Shares or other securities of the Company are
traded on a securities exchange, the Company shall not be required to
deliver any Shares or other securities covered by an Award unless and
until such Shares or other securities have been admitted for trading
on such securities exchange.
Section 7. Amendment and Termination; Adjustments
A. Amendments to the Plan. The Board may amend, alter, suspend, discontinue
or terminate the Plan at any time; provided, however, that, notwithstanding any
other provision of the Plan or any Award Agreement, without the approval of the
shareholders of the Company, no such amendment, alteration, suspension,
discontinuation or termination shall be made that, absent such approval would
violate the rules or regulations of the Nasdaq National Market or any other
securities exchange that is applicable to the Company.
9
B. Amendments to Awards. The Committee may waive any conditions of or
rights of the Company under any outstanding Award, prospectively or
retroactively. Except as otherwise provided herein or in an Award Agreement, the
Committee may not amend, alter, suspend, discontinue or terminate any
outstanding Award, prospectively or retroactively, if such action would
adversely affect the rights of the holder of such Award, without the consent of
the Participant or holder or beneficiary thereof. Notwithstanding the foregoing,
without the prior approval of Enzon's stockholders, options issued under this
Plan will not be repriced, replaced, or regranted through cancellation, or by
lowering the option exercise price of a previously granted Award.
C. Correction of Defects, Omissions and Inconsistencies. The Committee may
correct any defect, supply any omission or reconcile any inconsistency in the
Plan or any Award in the manner and to the extent it shall deem desirable to
carry the Plan into effect.
Section 8. Income Tax Withholding
In order to comply with all applicable national, federal, state or local
income tax laws or regulations, the Company may take such action as it deems
appropriate to ensure that all applicable national, federal, state or local
payroll, withholding, income or other taxes, which are the sole and absolute
responsibility of a Participant, are withheld or collected from such
Participant. In order to assist a Participant in paying all or a portion of the
national, federal, state and local taxes to be withheld or collected upon
exercise or receipt of (or the lapse of restrictions relating to) an Award, the
Committee, in its discretion and subject to such additional terms and conditions
as it may adopt, may permit the Participant to satisfy such tax obligation by
(i) electing to have the Company withhold a portion of the Shares otherwise to
be delivered upon exercise or receipt of (or the lapse of restrictions relating
to) such Award with a Fair Market Value equal to the amount of such taxes or
(ii) delivering to the Company Shares other than Shares issuable upon exercise
or receipt of (or the lapse of restrictions relating to) such Award with a Fair
Market Value equal to the amount of such taxes. The election, if any, must be
made on or before the date that the amount of tax to be withheld is determined.
Section 9. General Provisions
A. No Rights to Awards. No Eligible Person, Participant or other Person
shall have any claim to be granted any Award under the Plan, and there is no
obligation for uniformity of treatment of Eligible Persons, Participants or
holders or beneficiaries of Awards under the Plan. The terms and conditions of
Awards need not be the same with respect to any Participant or with respect to
different Participants.
B. Plan Provisions Control. In the event that any provision of an Award
Agreement conflicts with or is inconsistent in any respect with the terms of the
Plan as set forth herein or subsequently amended, the terms of the Plan shall
control.
C. No Rights of Shareholders. Except with respect to Shares of Restricted
Stock as to which the Participant has been granted the right to vote, neither a
Participant nor the Participant's legal representative shall be, or have any of
the rights and privileges of, a stockholder of the Company with respect to any
Shares issuable to such Participant upon the exercise or payment of any Award,
in whole or in part, unless and until such Shares have been issued in the name
of such Participant or such Participant's legal representative without
restrictions thereto.
10
D. No Limit on Other Compensation Arrangements. Nothing contained in the
Plan shall prevent the Company or any Affiliate from adopting or continuing in
effect other or additional compensation arrangements, and such arrangements may
be either generally applicable or applicable only in specific cases.
E. No Right to Employment. The grant of an Award shall not be construed as
giving a Participant the right to be retained in the employ of the Company or
any Affiliate, nor will it affect in any way the right of the Company or an
Affiliate to terminate such employment at any time, with or without cause. In
addition, the Company or an Affiliate may at any time dismiss a Participant from
employment free from any liability or any claim under the Plan or any Award,
unless otherwise expressly provided in the Plan or in any Award Agreement.
Nothing in this Plan shall confer on any person any legal or equitable right
against the Company or any Affiliate, directly or indirectly, or give rise to
any cause of action at law or in equity against the Company or an Affiliate. The
Awards granted hereunder shall not form any part of the wages or salary of any
Eligible Person for purposes of severance pay or termination indemnities,
irrespective of the reason for termination of employment. Under no circumstances
shall any person ceasing to be an employee of the Company or any Affiliate be
entitled to any compensation for any loss of any right or benefit under the Plan
which such employee might otherwise have enjoyed but for termination of
employment, whether such compensation is claimed by way of damages for wrongful
or unfair dismissal, breach of contract or otherwise. By participating in the
Plan, each Participant shall be deemed to have accepted all the conditions of
the Plan and the terms and conditions of any rules and regulations adopted by
the Committee and shall be fully bound thereby.
F. Governing Law. The validity, construction and effect of the Plan or any
Award, and any rules and regulations relating to the Plan or any Award, shall be
determined in accordance with the internal laws, and not the law of conflicts,
of the State of Delaware.
G. Severability. If any provision of the Plan or any Award is or becomes or
is deemed to be invalid, illegal or unenforceable in any jurisdiction or would
disqualify the Plan or any Award under any law deemed applicable by the
Committee, such provision shall be construed or deemed amended to conform to
applicable laws, or if it cannot be so construed or deemed amended without, in
the determination of the Committee, materially altering the purpose or intent of
the Plan or the Award, such provision shall be stricken as to such jurisdiction
or Award, and the remainder of the Plan or any such Award shall remain in full
force and effect.
H. No Trust or Fund Created. Neither the Plan nor any Award shall create or
be construed to create a trust or separate fund of any kind or a fiduciary
relationship between the Company or any Affiliate and a Participant or any other
Person. To the extent that any Person acquires a right to receive payments from
the Company or any Affiliate pursuant to an Award, such right shall be no
greater than the right of any unsecured general creditor of the Company or any
Affiliate.
I. Other Benefits. No compensation or benefit awarded to or realized by any
Participant under the Plan shall be included for the purpose of computing such
Participant's compensation under any compensation-based retirement, disability,
or similar plan of the Company unless required by law or otherwise provided by
such other plan.
11
J. No Fractional Shares. No fractional Shares shall be issued or delivered
pursuant to the Plan or any Award, and the Committee shall determine whether
cash shall be paid in lieu of any fractional Shares or whether such fractional
Shares or any rights thereto shall be canceled, terminated or otherwise
eliminated.
K. Headings. Headings are given to the Sections and subsections of the Plan
solely as a convenience to facilitate reference. Such headings shall not be
deemed in any way material or relevant to the construction or interpretation of
the Plan or any provision thereof.
Section 10. Effective Date of the Plan.
The Plan shall be effective on December 4, 2001 subject to approval by the
shareholders of the Company on such date.
Section 11. Term of the Plan.
No Award shall be granted under the Plan ten years after the effective date
or any earlier date of discontinuation or termination established pursuant to
Section 7A of the Plan. However, unless otherwise expressly provided in the Plan
or in an applicable Award Agreement, any Award theretofore granted may extend
beyond such date, and the authority of the Committee provided for hereunder with
respect to the Plan and any Awards, and the authority of the Board to amend the
Plan, shall extend beyond the termination of the Plan.
12
APPENDIX C
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
ENZON PHARMACEUTICALS, INC.
The undersigned, Jeffrey H. Buchalter, being the President and Chief
Executive Officer of Enzon Pharmaceuticals, Inc., a corporation organized and
existing under the laws of the State of Delaware (the "Corporation"), hereby
certifies as follows:
FIRST: The present name of the corporation (hereinafter called the
"Corporation") is Enzon Pharmaceuticals, Inc.
SECOND: The name under which the corporation was originally incorporated is
Enzon, Inc. and the date of filing the original certificate of incorporation of
the Corporation with the Secretary of State of the State of Delaware is May 11,
1983.
THIRD: This Amended and Restated Certificate of Incorporation has been duly
adopted by the Corporation's Board of Directors and stockholders pursuant to the
provisions of Sections 242 and 245 of the General Corporation Law of the State
of Delaware in the form set forth as follows:
1. Name. The name of the corporation is Enzon Pharmaceuticals, Inc.
2. Address; Registered Agent. The Corporation's registered office in the
State of Delaware is located at Corporation Trust Center, 1209 Orange Street,
City of Wilmington, County of New Castle and the name of its registered agent at
such address is The Corporation Trust Company.
3. Purpose. The nature of the business and purposes to be conducted or
promoted by the Corporation are to engage in, carry on and conduct any lawful
act or activity for which corporations may be organized under the General
Corporation Law of Delaware.
4. Number of Shares. (A) The total number of shares of capital stock which
the Corporation shall have authority to issue is 173,000,000 shares, of which
170,000,000 shares shall be Common Stock, par value $.01 per share, and
3,000,000 shares shall be Preferred Stock, par value $.01 per share.
(B) The Preferred Stock may be issued from time to time in one or more
series. The Board of Directors of the Corporation is hereby expressly authorized
to provide, by resolution or resolutions duly adopted by it prior to issuance,
for the creation of each such series and to fix the designation and the powers,
preferences, rights, qualifications, limitations and restrictions relating to
the shares of each such series. The authority of the Board of Directors with
respect to each series of Preferred Stock shall include, but not be limited to,
determining the following:
a. the designation of such series, the number of shares to constitute such
series and the stated value thereof if different from the par value thereof;
b. whether the shares of such series shall have voting rights, in addition
to any voting rights provided by law, and, if so, the terms of such voting
rights, which may be general or limited;
c. the dividends, if any, payable on such series, whether any such
dividends shall be cumulative, and, if so, from what dates, the conditions and
dates upon which such dividends shall be payable, and the preference or relation
which such dividends shall bear to the dividends payable on any shares of stock
of any other class or any other series of Preferred Stock;
d. whether the shares of such series shall be subject to redemption by the
Corporation, and, if so, the times, prices and other conditions of such
redemption;
e. the amount or amounts payable upon shares of such series upon, and the
rights of the holders of such series in, the voluntary or involuntary
liquidation, dissolution or winding up, or upon any distribution of the assets,
of the Corporation;
f. whether the shares of such series shall be subject to the operation of a
retirement or sinking fund and, if so, the extent to and manner in which any
such retirement or sinking fund shall be applied to the purchase or redemption
of the shares of such series for retirement or other corporation purposes and
the terms and provisions relating to the operation thereof;
g. whether the shares of such series shall be convertible into, or
exchangeable for, shares of stock of any other class or any other series of
Preferred Stock or any other securities and, if so, the price or prices or the
rate or rates of conversion or exchange and the method, if any, of adjusting the
same, and any other terms and conditions of conversion or exchange;
h. the conditions or restrictions, if any, upon the creation of
indebtedness of the Corporation or upon the issue of any additional stock,
including additional shares of such series or of any other series of Preferred
Stock or of any other class; and
i. any other powers, preferences and relative, participating, optional and
other special rights, and any qualifications, limitations and restrictions,
thereof.
The powers, preferences and relative, participating, optional and other
special rights of each series of Preferred Stock, and the qualifications,
limitations or restrictions thereof, if any, may differ from those of any and
all other series at any time outstanding. All shares of any one series of
Preferred Stock shall be identical in all respects with all other shares of such
series, except that shares of any one series issued at different times may
differ as to the dates from which dividends thereof shall be cumulative.
Pursuant to the authority conferred by this Article Fourth upon the Board
of Directors of the Corporation, the Board of Directors created a series of
Preferred Stock designated as Series B Preferred Stock by filing a Certificate
of Designations of the Corporation with the Secretary of State of the State of
Delaware (the "Secretary of State") on May 22, 2002, and the voting powers,
designations, preferences and relative, participating, optional or other special
rights, and the qualifications, limitations or restrictions thereof, of the
Corporation's Series B Preferred Stock are set forth in Appendix A hereto and
are incorporated herein by reference.
5. Name and Address of Incorporator. The name and mailing address of the
incorporator is Dan Brecher, 260 Madison Avenue, New York, New York, 10016.
6. Election of Directors. Members of the Board of Directors may be elected
either by written ballot or by voice vote.
7. Adoption, Amendment and/or Repeal of By-Laws. The Board of Directors may
from time to time (after adoption by the undersigned of the original by-laws of
the Corporation) make, alter or repeal the by-laws of the Corporation; provided,
that any by-laws made, amended or repealed by the Board of Directors may be
amended or repealed, and any by-laws may be made, by the stockholders of the
Corporation.
8. Compromises and Arrangements. Whenever a compromise or arrangement is
proposed between the Corporation and its creditors or any class of them and/or
between this Corporation and its stockholders or any class of them, any court of
equitable jurisdiction within the State of Delaware may, on the application in a
summary way of this Corporation or of any creditor or stockholder thereof or on
the application of any receiver or receivers appointed for this Corporation
under the provisions of section 291 of Title 8 of the Delaware Code or on the
application of trustees in dissolution or of any receiver or receivers appointed
for this Corporation under the provisions of section 279 of Title 8 of the
Delaware Code, order a meeting of the creditors or class of creditors, and/or of
the stockholders or class of stockholders of this Corporation, as the case may
be, to be summoned in such manner as the said court directs. If a majority in
number representing three-fourths in value of the creditors or class of
2
creditors, and/or of the stockholders or class of stockholders of this
Corporation, as the case may be, agree to any compromise or arrangement and to
any reorganization of this Corporation as consequence of such compromise or
arrangement, the said compromise or arrangement and the said reorganization
shall, if sanctioned by the court to which the said application has been made,
be binding on all the creditors or class of creditors, and/or on all the
stockholders or class of stockholders, of this Corporation, as the case may be,
and also on this Corporation.
9. Number of Directors. (A) The Board of Directors shall consist of not
less than three nor more than fifteen directors, the exact number of directors
to be determined from time to time by resolution adopted by affirmative vote of
a majority of the whole Board of Directors, and such exact number shall be four
until otherwise determined by resolution adopted by affirmative vote of a
majority of the whole Board of Directors. As used in this Article 9, the term
"whole Board" means the total number of directors, which the Corporation would
have if there were no vacancies. The Board of Directors shall divide the
directors into three classes and, when the number of directors is changed, shall
determine the class or classes to which the increased or decreased number of
directors shall be apportioned; provided, that no decrease in the number of
directors shall affect the term of any director then in office. Notwithstanding
the foregoing, and except as otherwise required by law, whenever the holders of
any one or more series of Preferred Stock shall have the right, voting
separately as a class, to elect one or more directors of the Corporation, the
terms of the director or directors elected by such holders shall expire at the
next succeeding annual meeting of stockholders. The term of office of directors
elected at the 1986 Annual Meeting of Stockholders held on January 20, 1987
shall be as follows: the term of office of directors of the first class shall
expire at the first annual meeting of stockholders after their election; the
term of office of directors of the second class shall expire at the second
annual meeting of stockholders after their election; and the term of office of
directors of the third class shall expire at the third annual meeting of
stockholders after their election; and as to directors of each class, when their
respective successors are elected and qualified. At each annual meeting of
stockholders subsequent to the 1986 Annual Meeting of Stockholders, directors
elected to succeed those whose terms are expiring shall be elected for a term of
office to expire at the third succeeding annual meeting of stockholders and when
their respective successors are elected and qualified.
(B) Vacancies in the Board of Directors, however caused, and newly created
directorships shall be filled solely by a majority vote of the directors then in
office, whether or not a quorum, and any director so chosen shall hold office
for a term expiring at the annual meeting of stockholders at which the term of
the class to which the director has been chosen expires and when the director's
successor is elected and qualified.
(C) The affirmative vote of the holders of not less than two-thirds of the
outstanding voting shares of capital stock of the Corporation entitled to vote
generally in the election of directors shall be required to amend, alter, change
or repeal, or adopt any provisions inconsistent with this Article 9, provided,
however, that this paragraph shall not apply to, and such two-thirds vote shall
not be required for, any amendment, alteration, change, repeal or adoption of
any inconsistent provision declared advisable by the Board of Directors by the
affirmative vote of two-thirds of the Board and submitted to stockholders for
their consideration, but only if a majority of the members of the Board of
Directors acting upon such matter shall be Continuing Directors. The term
"Continuing Director" shall mean a director who was a member of the Board as of
October 1, 1986.
10. Limitation of Directors' Liability; Indemnification. A director of the
Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director,
except for liability (i) for any breach of the director's duty of loyalty to the
Corporation or its stockholders, (ii) for acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, (iii) under
Section 174 of the Delaware General Corporation Law, as the same exists or
hereafter may be amended, or (iv) for any transaction from which the director
derived an improper personal benefit. If the Delaware General Corporation Law
hereafter is amended to authorize the further elimination or limitation of the
liability of directors, then the liability of a director of the Corporation, in
addition to the limitation on personal liability provided herein, shall be
limited to the fullest extent permitted by the amended Delaware General
Corporation Law. Any repeal or modification of this paragraph by the
stockholders of the Corporation shall be prospective only, and shall not
adversely affect any limitation on the personal liability of a director of the
corporation existing at the time of such repeal or modification.
(SIGNATURE ON FOLLOWING PAGE)
3
I, Jeffrey H. Buchalter, President and Chief Executive Officer of the
Corporation, for the purpose of amending and restating the Corporation's
Certificate of Incorporation pursuant to the Delaware General Corporation Law,
do make this certificate, hereby declaring and certifying that the facts stated
herein are true and this is my act and deed on behalf of the Corporation this
___ day of May, 2006.
By: Jeffrey H. Buchalter
Title: President and Chief Executive Officer
4
CERTIFICATE OF DESIGNATION, PREFERENCES AND RIGHTS OF
SERIES B PREFERRED STOCK
OF
ENZON, INC.
Pursuant to Section 151 of the
General Corporation Law of the State of Delaware
Enzon, Inc. (the "Corporation"), a corporation organized and existing under
the laws of the State of Delaware, does hereby certify that, pursuant to the
authority conferred on the Board of Directors of the Corporation by the
Certificate of Incorporation, as amended, of the Corporation and in accordance
with Section 151 of the General Corporation Law of the State of Delaware, the
Board of Directors of the Corporation adopted the following resolution creating
the preferences and rights of its series of 600,000 shares of Preferred Stock,
no shares of which have been issued, designated as " Series B Preferred Stock."
RESOLVED, that pursuant to the authority vested in the Board of Directors
of this Corporation in accordance with the provisions of its Certificate of
Incorporation, as amended, a series of preferred stock of the Corporation is
hereby created and the designation and amount of such series and the voting
powers, preferences and relative, participating, optional and other special
rights of the shares of such series, and the qualifications, limitations or
restrictions thereof are as follows:
a. Designation and Amount. The shares of such series shall be designated as
"Series B Preferred Stock" (the " Series B Preferred Stock") and the number of
shares constituting the Series B Preferred Stock shall be six hundred thousand
(600,000). Such number of shares may be increased or decreased by resolution of
the Board of Directors; provided, that no decrease shall reduce the number of
shares of Series B Preferred Stock to a number less than the number of shares
then outstanding plus the number of shares reserved for issuance upon the
exercise of outstanding options, rights or warrants or upon the conversion of
any outstanding securities issued by the Corporation convertible into Series B
Preferred Stock.
b. Dividends and Distributions.
(i) Subject to the rights of the holders of any shares of any series of
preferred stock (or any similar stock) ranking prior and superior to the Series
B Preferred Stock with respect to dividends, the holders of shares of Series B
Preferred Stock, in preference to the holders of Common Stock, par value $.01
(the "Common Stock"), of the Corporation, and of any other junior stock, shall
be entitled to receive, when, as and if declared by the Board of Directors out
of funds legally available for the purpose, quarterly dividends payable in cash
on the first day of March, June, September and December in each year (each such
date being referred to herein as a "Quarterly Dividend Payment Date"),
commencing on the first Quarterly Dividend Payment Date after the first issuance
of a share or fraction of a share of Series B Preferred Stock, in an amount per
share (rounded to the nearest cent) equal to the greater of (a) $1.00 or (b)
subject to the provision for adjustment hereinafter set forth, 1,000 times the
aggregate per share amount of all cash dividends, and 1,000 times the aggregate
per share amount (payable in kind) of all non-cash dividends or other
distributions, other than a dividend payable in shares of Common Stock or a
subdivision of the outstanding shares of Common Stock (by reclassification or
otherwise), declared on the Common Stock since the immediately preceding
Quarterly Dividend Payment Date or, with respect to the first Quarterly Dividend
Payment Date, since the first issuance of any share or fraction of a share of
Series B Preferred Stock. In the event the Corporation shall at any time after
June 3, 2002, declare or pay any dividend on the Common Stock payable in shares
of Common Stock, or effect a subdivision or combination or consolidation of the
1
outstanding shares of Common Stock (by reclassification or otherwise) into a
greater or lesser number of shares of Common Stock, then in each such case the
amount to which holders of shares of Series B Preferred Stock were entitled
immediately prior to such event under clause (b) of the preceding sentence shall
be adjusted by multiplying such amount by a fraction, the numerator of which is
the number of shares of Common Stock outstanding immediately after such event
and the denominator of which is the number of shares of Common Stock that were
outstanding immediately prior to such event.
(ii) The Corporation shall declare a dividend or distribution on the Series
B Preferred Stock as provided in paragraph (A) of this Section immediately after
it declares a dividend or distribution on the Common Stock (other than a
dividend payable in shares of Common Stock or a subdivision of the outstanding
Common Stock); provided that, in the event no dividend or distribution shall
have been declared on the Common Stock during the period between any Quarterly
Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, a
dividend of $1.00 per share on the Series B Preferred Stock shall nevertheless
be payable, out of funds legally available for such purpose, on such subsequent
Quarterly Dividend Payment Date.
(iii) Dividends shall begin to accrue and be cumulative on outstanding
shares of Series B Preferred Stock from the Quarterly Dividend Payment Date next
preceding the date of issue of such shares, unless the date of issue of such
shares is prior to the record date for the first Quarterly Dividend Payment
Date, in which case dividends on such shares shall begin to accrue from the date
of issue of such shares, or unless the date of issue is a Quarterly Dividend
Payment Date or is a date after the record date for the determination of holders
of shares of Series B Preferred Stock entitled to receive a quarterly dividend
and before such Quarterly Dividend Payment Date, in either of which events such
dividends shall begin to accrue and be cumulative from such Quarterly Dividend
Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends
paid on the shares of Series B Preferred Stock in an amount less than the total
amount of such dividends at the time accrued and payable on such shares shall be
allocated pro rata on a share-by-share basis among all such shares at the time
outstanding. The Board of Directors may fix a record date for the determination
of holders of shares of Series B Preferred Stock entitled to receive payment of
a dividend or distribution declared thereon, which record date shall be not more
than 60 days prior to the date fixed for the payment thereof.
c. Voting Rights. The holders of shares of Series B Preferred Stock shall
have the following voting rights:
(i) Subject to the provision for adjustment hereinafter set forth, each
share of Series B Preferred Stock shall entitle the holder thereof to 1,000
votes on all matters submitted to a vote of the stockholders of the Corporation.
In the event the Corporation shall at any time after June 3, 2002, declare or
pay any dividend on the Common Stock payable in shares of Common Stock, or
effect a subdivision or combination or consolidation of the outstanding shares
of Common Stock (by reclassification or otherwise) into a greater or lesser
number of shares of Common Stock, then in each such case the number of votes per
share to which holders of shares of Series B Preferred Stock were entitled
immediately prior to such event shall be adjusted by multiplying such number by
a fraction, the numerator of which is the number of shares of Common Stock
outstanding immediately after such event and the denominator of which is the
number of shares of Common Stock that were outstanding immediately prior to such
event.
(ii) Except as otherwise provided herein, in any other Certificate of
Designation creating a series of preferred stock or any similar stock, or by
law, the holders of shares of Series B Preferred Stock and the holders of shares
of Common Stock and any other capital stock of the Corporation having general
voting rights shall vote together as one class on all matters submitted to a
vote of stockholders of the Corporation.
2
(iii) Except as set forth herein, or as otherwise provided by law, holders
of Series B Preferred Stock shall have no special voting rights and their
consent shall not be required (except to the extent they are entitled to vote
with holders of Common Stock as set forth herein) for taking any corporate
action.
4. Certain Restrictions.
(i) Whenever quarterly dividends or other dividends or distributions
payable on the Series B Preferred Stock as provided in Section 2 are in arrears,
thereafter and until all accrued and unpaid dividends and distributions, whether
or not declared, on shares of Series B Preferred Stock outstanding shall have
been paid in full, the Corporation shall not:
(1) declare or pay dividends, or make any other distributions, on any
shares of stock ranking junior (either as to dividends or upon liquidation,
dissolution or winding up) to the Series B Preferred Stock;
(2) declare or pay dividends, or make any other distributions, on any
shares of stock ranking on a parity (either as to dividends or upon liquidation,
dissolution or winding up) with the Series B Preferred Stock, except dividends
paid ratably on the Series B Preferred Stock and all such parity stock on which
dividends are payable or in arrears in proportion to the total amounts to which
the holders of all such shares are then entitled;
(3) redeem or purchase or otherwise acquire for consideration shares of any
stock ranking junior (either as to dividends or upon liquidation, dissolution or
winding up) to the Series B Preferred Stock, provided that the Corporation may
at any time redeem, purchase or otherwise acquire shares of any such junior
stock in exchange for shares of any stock of the Corporation ranking junior
(either as to dividends or upon dissolution, liquidation or winding up) to the
Series B Preferred Stock; or
(4) redeem or purchase or otherwise acquire for consideration any shares of
Series B Preferred Stock, or any shares of stock ranking on a parity with the
Series B Preferred Stock, except in accordance with a purchase offer made in
writing or by publication (as determined by the Board of Directors) to all
holders of such shares upon such terms as the Board of Directors, after
consideration of the respective annual dividend rates and other relative rights
and preferences of the respective series and classes, shall determine in good
faith will result in fair and equitable treatment among the respective series or
classes.
(ii) The Corporation shall not permit any subsidiary of the Corporation to
purchase or otherwise acquire for consideration any shares of stock of the
Corporation unless the Corporation could, under paragraph (A) of this Section 4,
purchase or otherwise acquire such shares at such time and in such manner.
e. Reacquired Shares. Any shares of Series B Preferred Stock purchased or
otherwise acquired by the Corporation in any manner whatsoever shall be retired
and cancelled promptly after the acquisition thereof. All such shares shall upon
their cancellation become authorized but unissued shares of preferred stock and
may be reissued as part of a new series of preferred stock subject to the
conditions and restrictions on issuance set forth herein, in the Certificate of
Incorporation, as amended, or in any other certificate of designation creating a
series of preferred stock or any similar stock or as otherwise required by law.
3
f. Liquidation, Dissolution or Winding Up. Upon any liquidation,
dissolution or winding up of the Corporation, no distribution shall be made (1)
to the holders of shares of stock ranking junior (either as to dividends or upon
liquidation, dissolution or winding up) to the Series B Preferred Stock unless,
prior thereto, the holders of shares of Series B Preferred Stock shall have
received the greater of (i) $1,000 per share, plus an amount equal to accrued
and unpaid dividends and distributions thereon, whether or not declared, to the
date of such payment, or (ii) an aggregate amount per share, subject to the
provision for adjustment hereinafter set forth, equal to 1,000 times the
aggregate amount to be distributed per share to holders of shares of Common
Stock, or (2) to the holders of shares of stock ranking on a parity (either as
to dividends or upon liquidation, dissolution or winding up) with the Series B
Preferred Stock, except distributions made ratably on the Series B Preferred
Stock and all such parity stock in proportion to the total amounts to which the
holders of all such shares are entitled upon such liquidation, dissolution or
winding up. In the event the Corporation shall at any time after June 3, 2002,
declare or pay any dividend on the Common Stock payable in shares of Common
Stock, or effect a subdivision or combination or consolidation of the
outstanding shares of Common Stock (by reclassification or otherwise) into a
greater or lesser number of shares of Common Stock, then in each such case the
aggregate amount to which holders of shares of Series B Preferred Stock were
entitled immediately prior to such event under clause (1)(ii) of the preceding
sentence shall be adjusted by multiplying such amount by a fraction the
numerator of which is the number of shares of Common Stock outstanding
immediately after such event and the denominator of which is the number of
shares of Common Stock that were outstanding immediately prior to such event.
g. Consolidation, Merger, Etc. In case the Corporation shall enter into any
consolidation, merger, combination or other transaction in which the shares of
Common Stock are exchanged for or changed into other stock or securities, cash
and/or any other property, then in any such case each share of Series B
Preferred Stock shall at the same time be similarly exchanged or changed into an
amount per share, subject to the provision for adjustment hereinafter set forth,
equal to 1,000 times the aggregate amount of stock, securities, cash and/or any
other property (payable in kind), as the case may be, into which or for which
each share of Common Stock is changed or exchanged. In the event the Corporation
shall at any time after June 3, 2002, declare or pay any dividend on the Common
Stock payable in shares of Common Stock, or effect a subdivision or combination
or consolidation of the outstanding shares of Common Stock (by reclassification
or otherwise) into a greater or lesser number of shares of Common Stock, then in
each such case the amount set forth in the preceding sentence with respect to
the exchange or change of shares of Series B Preferred Stock shall be adjusted
by multiplying such amount by a fraction, the numerator of which is the number
of shares of Common Stock outstanding immediately after such event and the
denominator of which is the number of shares of Common Stock that were
outstanding immediately prior to such event.
h. No Redemption. The shares of Series B Preferred Stock shall not be
redeemable.
i. Rank. The Series B Preferred Stock shall rank, with respect to the
payment of dividends and the distribution of assets, junior to all series of any
other class of the Corporation's preferred stock.
j. Fractional Shares. Series B Preferred Stock may be issued in fractions
of a share which shall entitle the holder, in proportion to such holder's
fractional shares, to receive dividends, participate in distributions and to
have the benefit of all other rights of holders of Series B Preferred Stock.
k. Amendment. The Certificate of Incorporation, as amended of the
Corporation shall not be amended in any manner which would materially alter or
change the powers, preferences or rights of the Series B Preferred Stock so as
to affect them adversely without the affirmative vote of the holders of at least
two-thirds of the outstanding shares of Series B Preferred Stock, voting
together as a single class.
4
Proxy Card
ENZON PHARMACEUTICALS, INC.
Annual Meeting of Stockholders May 18, 2006
This Proxy Is Solicited on Behalf of the Board of Directors
Jeffrey H. Buchalter and Craig A. Tooman and each of them, as proxies, with
full power of substitution in each of them, are hereby authorized to represent
and to vote, as designated below and on the reverse side, on all proposals and
in the discretion of the proxies on such other matters as may properly come
before the annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (the
"Company") to be held on May 18, 2006 or any adjournment(s), postponement(s), or
other delay(s) thereof (the "Annual Meeting"), all shares of stock of the
Company to which the undersigned is entitled to vote at the Annual Meeting.
UNLESS OTHERWISE DIRECTED, THIS PROXY WILL BE VOTED "FOR" PROPOSALS 1, 2, 3
AND 4 AND WILL BE VOTED IN THE DISCRETION OF THE PROXIES ON SUCH OTHER MATTERS
AS MAY PROPERLY COME BEFORE THE ANNUAL MEETING. THE BOARD OF DIRECTORS HAS
PROPOSED AND RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" PROPOSALS 1, 2, 3 AND 4.
(1) Election of the following nominee as Class I Director to serve in such capacity until his successor is
duly elected and qualified:
Phillip M. Renfro
(Authority to vote for the nominee may be withheld by lining through the name of such nominee.)
/ / FOR the nominee / / WITHHOLD authority for the nominee
(2) Approval of the amendment of the 2001 Incentive Stock Plan to increase the number of shares of common
stock issuable thereunder by an additional 4,000,000 shares.
/ / FOR / / AGAINST / / ABSTAIN
(3) To approve the amendment and restatement of our Restated Certificate of Incorporation to increase the
number of authorized shares of common stock from 90,000,000 shares to 170,000,000 shares.
/ / FOR / / AGAINST / / ABSTAIN
(4) Ratification of the selection of KPMG LLP to audit the consolidated financial statements of the Company
for the fiscal year ending December 31, 2006.
/ / FOR / / AGAINST / / ABSTAIN
/ /Please check this box if you expect to attend the Annual Meeting in person.
(Please sign exactly as name appears to the left, date and return. If shares are held by
joint tenants, both should sign. When signing as attorney, executor, administrator,
trustee or guardian, please give full title as such. If a corporation, please sign in
full corporate name by president or other authorized officer. If a partnership, please
sign in partnership name by authorized person.)
Date:
______________________________________
Sign Here
________________________________________
Signature (if held jointly)
________________________________________
Capacity (Title or Authority, i.e. Executor, Trustee)
PLEASE SIGN, DATE AND MAIL YOUR PROXY TODAY
[GRAPHIC OMITTED][GRAPHIC OMITTED]
HELLER EHRMAN LLP
Molly.Gardner@hellerehrman.com
Direct +1.212.847.8757
Via EDGAR Main +1.212.832.8300
Fax +1.212.763.7600
March 22, 2006
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re: Enzon Pharmaceuticals, Inc. Preliminary Proxy
On behalf of Enzon Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), I enclose for filing with the Securities and Exchange Commission
(the "Commission") pursuant to Rule 14a-6(b) under the Securities Exchange Act
of 1934 (the "Exchange Act") a preliminary copy of (1) the Company's Proxy
Statement relating to its 2006 Annual Meeting, (2) a Notice of Annual Meeting
and (3) the Proxy Card. No fee is required in connection with this filing.
Pursuant to Rule 14a-6(d) under the Exchange Act, we hereby advise you that
the Company anticipates releasing definitive copies of the proxy materials to
its stockholders on or about April 18, 2006.
If we can respond to any comments or questions, please do not hesitate to
contact the undersigned at (212) 832-8300.
Very truly yours,
/s/ MOLLY E. GARDNER
Molly E. Gardner
Enclosure
Heller Ehrman LLP Times Square Tower 7 Times Square
New York, NY 10036-6524 www.hellerehrman.com
- ------------------------------------------------------------------------------
Anchorage Beijing Hong Kong Los Angeles Madison, WI
New York San Diego San Francisco Seattle
Silicon Valley Singapore Washington, D.C.
March 22, 2006